var title_f24_20_24896="2D TTE and M mode images normal tricuspid valve";
var content_f24_20_24896=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Two-dimensional transthoracic echocardiogram (2D TTE) and M mode images showing a normal tricuspid valve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 263px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The tricuspid valve (tv) can be imaged from the precordial long axis view (panel A). In panel B, the M-mode beam is directed through the septal leaflet (inset); an M-mode echocardiogram typically shows a single anteriorly moving leaflet. In this example, atrial fibrillation is present, resulting in a wave form that is of irregular duration, shows early diastolic opening, and occasional small movements arising from rapid fibrillatory contraction. Additionally, the right atrium (RA) is enlarged.",
"    <div class=\"footnotes\">",
"     RV: right ventricle.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_20_24896=[""].join("\n");
var outline_f24_20_24896=null;
var title_f24_20_24897="Insertion of ring pessary";
var content_f24_20_24897=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Insertion of the ring vaginal pessary",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Milex Products, Inc., Chicago, IL.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_20_24897=[""].join("\n");
var outline_f24_20_24897=null;
var title_f24_20_24898="Chrn thromboemboli angio II";
var content_f24_20_24898=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    Right-sided pulmonary angiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Compared to the anterior view (A), the lateral view (B) more clearly shows complete obstruction of the right lower lobe artery immediately below the superior segment and right middle lobe arteries.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter F Fedullo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_20_24898=[""].join("\n");
var outline_f24_20_24898=null;
var title_f24_20_24899="Ligature uteroovarian pedicle";
var content_f24_20_24899=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Utero-ovarian pedicle during vaginal hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After cutting, the pedicle undergoes both suture ligature and suture tie ligation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_20_24899=[""].join("\n");
var outline_f24_20_24899=null;
var title_f24_20_24900="Scabies male genitalia";
var content_f24_20_24900=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scabies male genitalia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scabies. Pruritic papules and nodules are present on the penis and scrotum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_20_24900=[""].join("\n");
var outline_f24_20_24900=null;
var title_f24_20_24901="Cytomegalovirus immune globulin: Drug information";
var content_f24_20_24901=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cytomegalovirus immune globulin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/52/5956?source=see_link\">",
"    see \"Cytomegalovirus immune globulin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/16/16645?source=see_link\">",
"    see \"Cytomegalovirus immune globulin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F156155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      CytoGam&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4663230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      CytoGam&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F156175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Blood Product Derivative;",
"     </li>",
"     <li>",
"      Immune Globulin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F156157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prophylaxis of CMV disease in kidney transplant:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial dose (within 72 hours of transplant): 150 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-, 4-, 6-, and 8 weeks after transplant: 100 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12 and 16 weeks after transplant: 50 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prophylaxis of CMV disease in liver, lung, pancreas, or heart transplant:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial dose (within 72 hours of transplant): 150 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-, 4-, 6-, and 8 weeks after transplant: 150 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12 and 16 weeks after transplant: 100 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of severe CMV pneumonitis in hematopoietic stem cell transplant (unlabeled use; in combination with ganciclovir):",
"     </b>",
"     I.V.: 400 mg/kg on days 1, 2, and 7, followed by 200 mg/kg on day 14; if still symptomatic, may administer an additional 200 mg/kg on day 21 (Reed, 1988)",
"     <b>",
"      or",
"     </b>",
"     150 mg/kg twice weekly (Alexander, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F15670247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/16/16645?source=see_link\">",
"      see \"Cytomegalovirus immune globulin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Prophylaxis of CMV disease in kidney, liver, lung, pancreas, or heart transplant:",
"     </b>",
"     Children and Adolescents: I.V.: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F156158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F156159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution. Infuse at minimum rate possible.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15795927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F156142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CytoGam&reg;: 50 mg (&plusmn; 10 mg)/mL (50 mL) [contains sodium 20-30 mEq/L, human albumin, and sucrose 50 mg/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F156128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F156145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Administer through an I.V. line containing an in-line 15 micron filter (a 0.2 micron filter is also acceptable) using an infusion pump. Do not mix with other infusions; do not use if turbid. Begin infusion within 6 hours of entering vial, complete infusion within 12 hours of vial entry.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Initial dose:",
"     </i>",
"     Infuse at 15 mg/kg/hour. If no adverse reactions occur within 30 minutes, may increase rate to 30 mg/kg/hour. If no adverse reactions occur within the second 30 minutes, may increase rate to 60 mg/kg/hour; maximum rate of infusion: 75 mL/hour. Monitor closely after each rate change. If patient develops nausea, back pain, or flushing during infusion, slow the rate or temporarily stop the infusion. Discontinue if blood pressure drops or in case of anaphylactic reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Subsequent doses:",
"     </i>",
"     Infuse at 15 mg/kg/hour for 15 minutes; if no adverse reactions occur, may increase rate to 30 mg/kg/hour for 15 minutes; if no adverse reactions occur, may increase rate to 60 mg/kg/hour; maximum rate of infusion: 75 mL/hour.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F156180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infusion with other products is not recommended. If unavoidable, may be piggybacked into an I.V. line of sodium chloride, 2.5% dextrose in water, 5% dextrose in water, 10% dextrose in water, or 20% dextrose in water. Do not dilute more than 1:2. Do not admix with other medications.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F156143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis of cytomegalovirus (CMV) disease associated with kidney, lung, liver, pancreas, and heart transplants; concomitant use with ganciclovir should be considered in organ transplants (other than kidney) from CMV seropositive donors to CMV seronegative recipients",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F156171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive therapy in the treatment of CMV pneumonitis in solid organ transplant and in hematopoietic stem cell transplant",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F156182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       CytoGam&reg; may be confused with Cytoxan, Gamimune&reg; N",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F156173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;6%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Flushing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Chills, fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, muscle cramps",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal pain, acute renal failure, acute respiratory distress syndrome (ARDS), acute tubular necrosis, allergic reactions (systemic), anaphylactic shock, angioneurotic edema, anuria, apnea, aseptic meningitis syndrome (AMS), blood pressure decreased, bronchospasm, bullous dermatitis, BUN increased, cardiac arrest, coma, Coomb&rsquo;s test positive, cyanosis, dyspnea, epidermolysis, erythema multiforme, hemolysis, hypotension, hypoxemia, leukopenia, liver dysfunction, loss of consciousness, oliguria, osmotic nephrosis, pancytopenia, proximal tubular nephropathy, pulmonary edema, renal dysfunction, rigors, seizure, serum creatinine increased, Stevens-Johnson syndrome, thromboembolism, transfusion-related acute lung injury (TRALI), tremor, vascular collapse",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F156147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cytomegalovirus immune globulin (CMV-IGIV), other immunoglobulin preparations, or any component of the formulation; selective immunoglobulin A deficiency",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F156132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions can occur; monitor vital signs during infusion; discontinue immediately for hypotension or anaphylaxis; immediate treatment (including epinephrine 1:1000) should be available. Systemic allergic reactions are rare; may be treated with epinephrine and diphenhydramine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aseptic meningitis: Aseptic meningitis syndrome (AMS) has been reported with intravenous immune globulin administration (rare); may occur with high doses (&ge;2 g/kg). Symptoms include severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements and nausea and vomiting. Syndrome usually appears within several hours to 2 days following treatment; usually resolves within several days after discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemolysis: Intravenous immune globulin has been associated with antiglobulin hemolysis; monitor for signs of hemolytic anemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary edema: Monitor for adverse pulmonary events including transfusion-related acute lung injury (TRALI); noncardiogenic pulmonary edema has been reported with intravenous immune globulin use. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, and fever in the presence of normal left ventricular function and  usually occurs within 1-6 hours after infusion; may be managed with oxygen and respiratory support.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment:  Acute renal dysfunction (increased serum creatinine, oliguria, osmotic nephrosis, acute renal failure) can rarely occur; usually within 7 days of use (more likely with products stabilized with sucrose). Patients at risk for renal failure include the elderly, patients with preexisting renal disease, diabetes mellitus, volume depletion, sepsis, paraproteinemia, and nephrotoxic medications. In patients at risk of renal dysfunction, the rate of infusion and concentration of solution should be minimized. Discontinue if renal function deteriorates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombotic events: Thrombotic events have been reported with administration of intravenous immune globulin; patients at risk include those with advanced age or a history of atherosclerosis, cardiovascular and/or thrombotic risk factors, or known/suspected hyperviscosity. Consider a baseline assessment of blood viscosity in patients at risk for hyperviscosity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypovolemia: Patients should not be volume depleted prior to therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in patients &gt;65 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Albumin: Product is stabilized with albumin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sucrose: Product is stabilized with sucrose.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F156136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immune Globulins may diminish the therapeutic effect of Vaccines (Live).  Management: Live organism vaccination should be withheld for up to 6 months following immune globulin administration.  Live vaccine given immediately prior to immune globulin may require repeat vaccination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Yellow Fever Vaccine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F156138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F156149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F15672998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F4813545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection",
"     </b>",
"     (Cytogam Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/mL (50 mL): $1396.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F156140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function (BUN, serum creatinine prior to initial infusion and periodically thereafter); urine output; vital signs, including blood pressure (throughout infusion); signs/symptoms of infusion-related adverse reactions, anaphylaxis; signs and symptoms of hemolytic anemia; blood viscosity (baseline; in patients at risk for hyperviscosity); presence of antineutrophil antibodies (if TRALI is suspected); volume status; weight gain, clinical response",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F3462463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cytotect (PL);",
"     </li>",
"     <li>",
"      Megalotect (IL, TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F156131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CMV-IGIV is a preparation of immunoglobulin G (and trace amounts of IgA and IgM) derived from pooled healthy blood donors and contains a high titer of CMV antibodies; administration provides a passive source of antibodies against cytomegalovirus to attenuate or reduce the incidence of serious CMV disease",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alexander BT, Hladnik LM, Augustin KM, et al, &ldquo;Use of Cytomegalovirus Intravenous Immune Globulin for the Adjunctive Treatment of Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2010, 30(6):554-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/20/24901/abstract-text/20500045/pubmed\" id=\"20500045\" target=\"_blank\">",
"        20500045",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Humar A, and Snydman D, &ldquo;Cytomegalovirus in solid organ transplant recipients,&rdquo;",
"      <i>",
"       Am J Transplant",
"      </i>",
"      , 2009, 9(Suppl 4):578-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/20/24901/abstract-text/20070700/pubmed\" id=\"20070700\" target=\"_blank\">",
"        20070700",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kotton CN, Kumar D, Caliendo AM, et al, \"International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation,\"",
"      <i>",
"       Transplantation",
"      </i>",
"      2010, 89(7):779-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/20/24901/abstract-text/20224515/pubmed\" id=\"20224515\" target=\"_blank\">",
"        20224515",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reed EC, Bowden RA, Dandliker PS, et al, &ldquo;Efficacy of Cytomegalovirus Immunoglobulin in Marrow Transplant Recipients With Cytomegalovirus Pneumonia,&rdquo;",
"      <i>",
"       J Infect Dis",
"      </i>",
"      , 1987, 156(4):641-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/20/24901/abstract-text/3040870/pubmed\" id=\"3040870\" target=\"_blank\">",
"        3040870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reed EC, Bowden RA, Dandliker PS, et al, &ldquo;Treatment of Cytomegalovirus Pneumonia With Ganciclovir and Intravenous Cytomegalovirus Immunoglobulin in Patients With Bone Marrow Transplants,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1988, 109(10):783-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/20/24901/abstract-text/2847610/pubmed\" id=\"2847610\" target=\"_blank\">",
"        2847610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Renal Insufficiency and Failure Associated With Immune Globulin Intravenous Therapy - United States, 1985-1998.&rdquo;",
"      <i>",
"       MMWR",
"      </i>",
"      , 1999, 48(24):518-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/20/24901/abstract-text/10401909/pubmed\" id=\"10401909\" target=\"_blank\">",
"        10401909",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sokos DR, Berger M, and Lazarus HM, &ldquo;Intravenous Immunoglobulin: Appropriate Indications and Uses in Hematopoietic Stem Cell Transplantation,&rdquo;",
"      <i>",
"       Biol Blood Marrow Transplant",
"      </i>",
"      , 2002, 8(3):117-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/20/24901/abstract-text/11939601/pubmed\" id=\"11939601\" target=\"_blank\">",
"        11939601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zamora MR, Nicolls MR, Hodges TN, et al, &ldquo;Following Universal Prophylaxis With Intravenous Ganciclovir and Cytomegalovirus Immune Globulin, Valganciclovir is Safe and Effective for Prevention of CMV Infection Following Lung Transplantation,&rdquo;",
"      <i>",
"       Am J Transplant,",
"      </i>",
"      2004, 4(10):1635-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/20/24901/abstract-text/15367218/pubmed\" id=\"15367218\" target=\"_blank\">",
"        15367218",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9315 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-219.243.220.100-C5CC09C3EA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_20_24901=[""].join("\n");
var outline_f24_20_24901=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156155\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4663230\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156175\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156157\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15670247\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156158\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156159\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795927\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156142\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156128\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156145\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156180\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156143\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156171\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156182\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156173\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156147\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156132\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299116\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156136\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156138\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156149\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15672998\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4813545\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323090\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156140\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3462463\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156131\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9315\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9315|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/52/5956?source=related_link\">",
"      Cytomegalovirus immune globulin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/16/16645?source=related_link\">",
"      Cytomegalovirus immune globulin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_20_24902="Cosyntropin (tetracosactide): Drug information";
var content_f24_20_24902=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cosyntropin (tetracosactide): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/45/29397?source=see_link\">",
"    see \"Cosyntropin (tetracosactide): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F154800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cortrosyn&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F154801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cortrosyn&trade;;",
"     </li>",
"     <li>",
"      Synacthen&reg; Depot",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F154832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Systemic;",
"     </li>",
"     <li>",
"      Diagnostic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F154802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Diagnostic use: Screening of adrenocortical insufficiency:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cosyntropin",
"     <b>",
"      powder",
"     </b>",
"     for injection (I.M., I.V.)",
"     <b>",
"      or",
"     </b>",
"     cosyntropin",
"     <b>",
"      solution",
"     </b>",
"     for injection (I.V. only [manufacturer labeling does not recommend I.M. administration of solution for injection]):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Conventional dose:",
"     </i>",
"     0.25 mg;",
"     <b>",
"      Note:",
"     </b>",
"     Doses in the range of 0.25-0.75 mg have been used in clinical studies; however, maximal response is seen with 0.25 mg dose. When greater cortisol stimulation is needed, an I.V. infusion may be used: 0.25 mg administered at 0.04 mg/hour over 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Low-dose protocol (unlabeled dose):",
"     </i>",
"     1 mcg (Abdu, 1999);",
"     <b>",
"      Note:",
"     </b>",
"     The use of the low-dose protocol has been advocated by some clinicians, particularly in mild or secondary adrenal insufficiency. The low-dose protocol is not recommended in critically-ill patients (Marik, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Synacthen&reg; Depot (Canadian availability): I.M.: 1 mg administered as a single dose or once daily for 3 or 4 days (depending on method of testing; refer to manufacturer labeling for detailed information).",
"     <b>",
"      Note:",
"     </b>",
"     For patients with severe adrenal insufficiency, some clinicians administer dexamethasone on days that Synacthen&reg; Depot is administered to provide steroid coverage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Therapeutic use:",
"     </b>",
"     Synacthen&reg; Depot (Canadian availability): I.M. (",
"     <b>",
"      Note:",
"     </b>",
"     Titrate to lowest effective dose at the longest effective dosing interval): Initial for acute treatment: 1 mg daily for 3 days; maintenance dose is individualized: 0.5-1 mg every 2-3 days or twice weekly or 2 mg once weekly or less frequently",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Transferring from corticosteroids:",
"     </b>",
"     Synacthen&reg; Depot (Canadian availability): I.M.: Initial: 1 mg daily; gradually reduce steroid by 25% of original dose on successive days. Upon withdrawal from steroid adjust Synacthen&reg; Depot dose as needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Transferring from animal-derived ACTH:",
"     </b>",
"     Synacthen&reg; Depot (Canadian availability): I.M.: Conversion varies depending on product previously used. Manufacturer suggests that patients previously receiving ACTH gel 40 units daily should receive Synacthen&reg; Depot 0.5 mg every other day; adjust dose based on response, preferably by extending the dosing interval.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F154818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/45/29397?source=see_link\">",
"      see \"Cosyntropin (tetracosactide): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Diagnostic use: Screening of adrenocortical insufficiency:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cosyntropin",
"     <b>",
"      powder",
"     </b>",
"     for injection (I.M., I.V.)",
"     <b>",
"      or",
"     </b>",
"     cosyntropin",
"     <b>",
"      solution",
"     </b>",
"     for injection (I.V. only [manufacturer labeling does not recommend I.M. administration of solution for injection]):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &le;2 years: 0.125 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &gt;2 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Synacthen&reg; Depot (Canadian availability): I.M.: Children &gt;3 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Therapeutic use:",
"     </b>",
"     Synacthen&reg; Depot (Canadian availability): I.M.:",
"     <b>",
"      Note:",
"     </b>",
"     Titrate to lowest effective dose at the longest effective dosing interval.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 3-6 years: Initial: 0.25-0.5 mg daily; maintenance: 0.25-0.5 mg every 2-8 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 7-15 years: Initial: 0.25-1 mg daily; maintenance: 0.25-1 mg every 2-8 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;16 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Transferring from corticosteroids:",
"     </b>",
"     Synacthen&reg; Depot (Canadian availability): I.M.: Children &gt;3 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Transferring from animal-derived ACTH:",
"     </b>",
"     Synacthen&reg; Depot (Canadian availability): I.M.: Children &gt;3 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F154803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15043625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15043626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F154785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 0.25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortrosyn&trade;: 0.25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 0.25 mg/mL (1 mL)",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F15043640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Synacthen&reg; Depot: 1 mg/mL (1 mL) [contains benzyl alcohol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F154772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F154788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: May administer by I.V. injection over 2 minutes or as an I.V. infusion over 4-8 hours. Synacthen&reg; Depot (Canadian availability) should",
"     <b>",
"      not",
"     </b>",
"     be administered intravenously.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M.: May administer I.M. (reconstituted powder for injection only); cosyntropin injection",
"     <b>",
"      solution",
"     </b>",
"     is not recommended for I.M. administration (manufacturer recommendation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Synacthen&reg; Depot (Canadian availability): Shake ampul until uniform appearance; administer by I.M. injection in the buttocks. Self-administration by patient is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F154787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diagnostic test to differentiate primary adrenal from secondary (pituitary) adrenocortical insufficiency",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Synacthen&reg; Depot (Canadian availability): Additional indications: Treatment of various disease states (eg, collagen, dermatologic, endocrine, ocular, hemolytic). Consult manufacturer labeling for detailed list.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F154837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cortrosyn&reg; may be confused with colchicine, corticorelin, corticotropin, Cotazym&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cosyntropin may be confused with corticorelin, corticotropin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F154830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"     <b>",
"      Note:",
"     </b>",
"     Adverse events associated with other corticosteroids may be observed when Synacthen&reg; Depot (Canadian availability) is used for therapeutic purposes. Refer to corticosteroid monographs for comprehensive lists.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, hypertension, peripheral edema, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Whealing with redness at the injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, hypersensitivity reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Synacthen&reg; Depot (Canadian availability): Adrenal hemorrhage",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F154791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cosyntropin or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Synacthen&reg; Depot (Canadian availability):Additional contraindications: Treatment of asthma or other allergic conditions (increased risk of anaphylactic reactions); use in premature babies and neonates &lt;1 month; acute psychosis; untreated bacterial, fungal, and viral infections; active or latent peptic ulcer; refractory heart failure; Cushing&rsquo;s syndrome; treatment of primary adrenocortical insufficiency; adrenogenital syndrome",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F154776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Corticotropin allergy: Cortrosyn&trade;: Use with caution in patients with a history of allergic reactions to corticotropin or pre-existing allergic disease. Synacthen&reg; Depot (Canadian availability) is contraindicated in patients with allergic conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Synacthen&reg; Depot (Canadian availability): Hypersensitivity reactions (including severe reactions) may occur particularly in patients with asthma or other allergies and often within 30 minutes of administration; monitor for hypersensitivity for ~1 hour after administration. Prolonged use may increase the risk of allergic reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Synacthen&reg; Depot (Canadian availability): Use caution in patients with hypertension or thromboembolic disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Synacthen&reg; Depot (Canadian availability): Use caution in patients with nonspecific ulcerative colitis, diverticulitis, or recent intestinal anastomosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic disease: Synacthen&reg; Depot (Canadian availability): Enhanced effects may be observed in patients with cirrhosis of the liver.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infections: Synacthen&reg; Depot (Canadian availability): Use caution in patients with acute or chronic infections (especially varicella or vaccinia) or exanthematous and fungal diseases. Use with caution in patients with latent tuberculosis; treatment may reactivate latent tuberculosis. Rule out amebiasis prior to initiating therapy; may activate latent amebiasis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Synacthen&reg; Depot (Canadian availability): Use caution in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Not recommended for the treatment of optic neuritis; may increase frequency of new episodes. Consider routine eye exams in chronic users.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteoporosis: Synacthen&reg; Depot (Canadian availability): Use caution in patients with osteoporosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Pre-existing psychiatric conditions may be exacerbated by corticosteroid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal disease: Synacthen&reg; Depot (Canadian availability): Use caution in patients with renal insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Synacthen&reg; Depot (Canadian availability): Enhanced effects may be observed with hypothyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage forms specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Synacthen&reg; Depot (Canadian availability): Contains benzyl alcohol; avoid use in infants and children &lt;3 years of age; contraindicated in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunizations: Synacthen&reg; Depot (Canadian availability): Live vaccines should not be given concurrently.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgery/trauma: Synacthen&reg; Depot (Canadian availability): Augmentation or resumption of therapy may be necessary in patients undergoing surgery or subjected to trauma either during or within 1 year of therapy discontinuation; adjunctive rapid acting corticosteroids may be necessary during periods of stress.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6219534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ClonazePAM: Cosyntropin may enhance the hepatotoxic effect of ClonazePAM.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazepam: Cosyntropin may enhance the hepatotoxic effect of Diazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitrazepam: Cosyntropin may enhance the hepatotoxic effect of Nitrazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Cosyntropin may enhance the hepatotoxic effect of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Cosyntropin may enhance the hepatotoxic effect of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Cosyntropin may enhance the hepatotoxic effect of Primidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Cosyntropin may enhance the hepatotoxic effect of Valproic Acid.  Management: Avoid concomitant use of Synacthen Depot (dosage form available in Canada) with valproic acid.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F154782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13447516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F154805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Cosyntropin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg/mL (1 mL): $119.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Cortrosyn Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg (1): $127.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Cosyntropin Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg (1): $115.10",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15043638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Synacthen&reg; Depot (Canadian availability): Observe patient for ~1 hour after administration for signs/symptoms of hypersensitivity; for diagnosis of adrenocortical Insufficiency measure plasma cortisol prior to and 4-6 hours after injection; with prolonged use monitor blood pressure, weight, urinalysis, glucose, electrolytes, signs and symptoms of infection, cataract formation, intraocular pressure, bone mass density and growth in children, ECG (in children)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F154786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Normal baseline cortisol &gt;5 mcg/dL; normal response 30 minutes after cosyntropin injection: increase in serum cortisol concentration  of &gt;7 mcg/dL or peak response &gt;18 mcg/dL; plasma cortisol concentrations should be measured immediately before and exactly 30 minutes after a dose. If increase in plasma cortisol levels at 30 minutes is equivocal, consider repeat cortisol sampling at 60 and/or 90 minutes.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Synacthen&reg; Depot (Canadian availability): 5-hour test: Plasma cortisol levels double in first hour then increase more gradually; normal values at 5 hours: 37-66 mcg/dL; 3-day test (control phase days 1 and 2, dosing on days 3-5): compared to control phase, urinary cortisol excretion at least doubles on day 3 and further increases on days 4 and 5",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cortrosina (BR);",
"     </li>",
"     <li>",
"      Cortrosina Depot (BR);",
"     </li>",
"     <li>",
"      Cortrosinta Depot (PT);",
"     </li>",
"     <li>",
"      Cortrosyn (BE, HU);",
"     </li>",
"     <li>",
"      Cortrosyn Depot (AE, BE, BF, BG, BH, BJ, CI, CY, CZ, EG, ET, FR, GH, GM, GN, HK, HN, HU, IL, IQ, IR, IT, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, QA, SA, SC, SD, SL, SN, SY, TN, TW, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Nuvacthen Depot (ES);",
"     </li>",
"     <li>",
"      Synacthen (AT, AU, BE, CH, CZ, DE, DK, GB, IE, IT, KP, LU, NO, PL, SE);",
"     </li>",
"     <li>",
"      Synacthen Deposito (VE);",
"     </li>",
"     <li>",
"      Synacthen Depot (AE, AT, AU, BF, BG, BH, BJ, CH, CI, CN, CY, CZ, DK, EG, ET, FI, GB, GH, GM, GN, GR, HN, HR, IE, IL, IQ, IR, IT, JO, KE, KP, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NL, NO, OM, PL, PT, QA, SA, SC, SD, SE, SL, SN, SY, TN, TZ, UG, UY, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Synacthene (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F154775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates the adrenal cortex to secrete adrenal steroids (including hydrocortisone, cortisone), androgenic substances, and a small amount of aldosterone",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F154790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration of action: Synacthen&reg; Depot (Canadian availability): I.M.: Plasma concentrations of 200-300 pg/mL maintained for 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Synacthen&reg; Depot (Canadian availability): I.M.: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Synacthen&reg; Depot (Canadian availability): V",
"     <sub>",
"      d",
"     </sub>",
"     : ~43% of body weight",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Synacthen&reg; Depot (Canadian availability): 7 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, serum: I.M., I.V. push: ~1 hour; plasma cortisol levels rise in healthy individuals within 5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abdu TAM, Elhadd TA, Neary R, et al, &ldquo;Comparison of the Low Dose Short Synacthen Test (1 &mu;g), the Conventional Dose Short Synacthen Test (250 &mu;g), and the Insulin Tolerance Test for Assessment of the Hypothalamo-Pituitary-Adrenal Axis in Patients With Pituitary Disease,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 1999, 84(3):838-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/20/24902/abstract-text/10084558/pubmed\" id=\"10084558\" target=\"_blank\">",
"        10084558",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Annane D, Sebille V, Charpentier C, et al, &ldquo;Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(7):862-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/20/24902/abstract-text/12186604/pubmed\" id=\"12186604\" target=\"_blank\">",
"        12186604",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Broide J, Soferman R, Kivity S, et al, &ldquo;Low-Dose Adrenocorticotropin Test Reveals Impaired Adrenal Function in Patients Taking Inhaled Corticosteroids,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 1995, 80(4):1243-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/20/24902/abstract-text/7714095/pubmed\" id=\"7714095\" target=\"_blank\">",
"        7714095",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Carlet JM, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,&rdquo;",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2008, 34(1):17-60. Available at",
"      <a href=\"file://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616/pdf/134_2007_Article_934.pdf\" target=\"_blank\">",
"       file://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616/pdf/134_2007_Article_934.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/20/24902/abstract-text/18058085/pubmed\" id=\"18058085\" target=\"_blank\">",
"        18058085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/20/24902/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marik PE, &ldquo;Critical Illness-Related Corticosteroid Insufficiency,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2009, 135(1):181-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/20/24902/abstract-text/19136406/pubmed\" id=\"19136406\" target=\"_blank\">",
"        19136406",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marik PE, Pastores SM, Annane D, et al, &ldquo;Recommendations for the Diagnosis and Management of Corticosteroid Insufficiency in Critically Ill Adult Patients: Consensus Statements From an International Task Force by the American College of Critical Care Medicine,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(6):1937-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/20/24902/abstract-text/18496365/pubmed\" id=\"18496365\" target=\"_blank\">",
"        18496365",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sprung CL, Annane D, Keh D, et al, &ldquo;Hydrocortisone Therapy for Patients With Septic Shock,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(2):111-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/20/24902/abstract-text/18184957/pubmed\" id=\"18184957\" target=\"_blank\">",
"        18184957",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thaler LM and Blevins LS, &ldquo;The Low Dose (1-&mu;g) Adrenocorticotropin Stimulation Test in the Evaluation of Patients With Suspected Central Adrenal Insufficiency,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 1998, 83(8):2726-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/20/24902/abstract-text/9709938/pubmed\" id=\"9709938\" target=\"_blank\">",
"        9709938",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tordjman K, Jaffe A, Grazas N, et al, &ldquo;The Role of the Low Dose (1 microgram) Adrenocorticotropin Test in the Evaluation of Patients With Pituitary Diseases,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 1995, 80(4):1301-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/20/24902/abstract-text/7714104/pubmed\" id=\"7714104\" target=\"_blank\">",
"        7714104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9298 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-714CE7359B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_20_24902=[""].join("\n");
var outline_f24_20_24902=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154800\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154801\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154832\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154802\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154818\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154803\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15043625\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15043626\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154785\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15043640\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154772\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154788\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154787\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154837\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154830\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154791\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154776\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299097\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6219534\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154782\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13447516\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154805\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323079\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15043638\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154786\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038590\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154775\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154790\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9298\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9298|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/45/29397?source=related_link\">",
"      Cosyntropin (tetracosactide): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_20_24903="Neurovascular anatomy of the popliteal fossa";
var content_f24_20_24903=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Neurovascular anatomy of the popliteal fossa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 672px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Distal femoral fractures and dislocations of the knee joint can cause injury to nerves and blood vessels that travel through the popliteal fossa including the popliteal artery and vein, tibial nerve, and common peroneal nerve.",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_20_24903=[""].join("\n");
var outline_f24_20_24903=null;
var title_f24_20_24904="Pemphigus foliaceus histopathology";
var content_f24_20_24904=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pemphigus foliaceus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Blister formation within the superficial granular layer in pemphigus foliaceus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_20_24904=[""].join("\n");
var outline_f24_20_24904=null;
var title_f24_20_24905="Evaluation of the response to ACTH in adrenal insufficiency";
var content_f24_20_24905=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of the response to ACTH in adrenal insufficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/20/24905/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/20/24905/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/20/24905/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/20/24905/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/20/24905/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/20/24905/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/20/24905/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurements of early morning (eg, 6 to 8 AM) serum cortisol and 24-hour urinary steroid excretion can suggest the diagnosis of adrenal insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44777?source=see_link\">",
"     \"Diagnosis of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, these measurements often cannot establish the presence or absence of adrenal insufficiency and cannot distinguish among the three disturbances in the hypothalamic-pituitary-adrenal (HPA) axis that can cause deficient cortisol secretion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A primary adrenal disorder resulting in deficiency of cortisol (primary adrenal insufficiency or Addison's disease).",
"     </li>",
"     <li>",
"      A pituitary disorder resulting in deficiency of corticotropin (ACTH) secretion (secondary adrenal insufficiency).",
"     </li>",
"     <li>",
"      A hypothalamic disorder resulting in deficiency of corticotropin-releasing hormone (CRH) and secondarily of ACTH (tertiary adrenal insufficiency).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While the history, such as prior pituitary surgery, glucocorticoid therapy, or tuberculosis, may provide strong clues to the site of possible adrenal deficiency, measurement of plasma ACTH and the responses of the anterior pituitary gland and adrenal cortex to a variety of stimuli will confirm the diagnosis and define the site at which the defect exists. The stimuli used include ACTH,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    -induced hypocortisolemia and, rarely, insulin-induced hypoglycemia. The low-dose and high-dose ACTH stimulation tests have supplanted insulin-induced hypoglycemia in clinical practice (except in patients suspected to have very recent loss of ACTH secretory capacity). The results are similar to those obtained with insulin-induced hypoglycemia; in addition, ACTH tests can be performed without a clinician being present, and are less expensive.",
"   </p>",
"   <p>",
"    The low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24902?source=see_link\">",
"     ACTH stimulation test",
"    </a>",
"    is intermediate in sensitivity between the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    test and the insulin-induced hypoglycemia or high dose ACTH stimulation test. It may detect more subtle deficiency in cortisol secretion than the latter test because plasma ACTH does not increase as much [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/1\">",
"     1",
"    </a>",
"    ]; however, the clinical importance of this finding is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR DYNAMIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major problem with relying on unstimulated serum cortisol values as the basis for the diagnosis of adrenal insufficiency is that cortisol secretion is episodic. A single early morning serum cortisol value, if it falls within the range of normal, is inconclusive, although a patient with adrenal insufficiency is very unlikely to have a high-normal value. Furthermore, the normal range is broad, and a patient can have pituitary or adrenal insufficiency but maintain basal ACTH",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cortisol secretion within the range of normal. In patients with congenital adrenal hyperplasia, the range of basal concentrations of serum cortisol, 17-hydroxyprogesterone, and other adrenal steroids overlap the normal range. For these reasons, dynamic function tests should be performed when there is doubt about the status of hypothalamic-pituitary-adrenal (HPA) function.",
"   </p>",
"   <p>",
"    Nevertheless, an early morning serum cortisol value can be very helpful in excluding adrenal insufficiency. A serum cortisol concentration greater than 11",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (300",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    makes it unlikely that the patient has clinically important hypothalamic-pituitary-adrenal insufficiency; in contrast, a value below 3",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (80",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    makes adrenal insufficiency very likely [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Similarly, a salivary cortisol concentration at 8 AM above 5.8",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (16",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    excludes adrenal insufficiency, whereas a value below about 1.8",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (5",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    makes the probability of adrenal insufficiency high. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/132?source=see_link\">",
"     \"Measurement of cortisol in serum and saliva\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dynamic testing is performed to establish the diagnosis in patients with equivocal serum cortisol values in whom hypoadrenalism is suspected. With simultaneous measurement of the plasma ACTH, these tests can also distinguish between primary and secondary or tertiary adrenal insufficiency. Distinction between hypothalamic and pituitary causes of hypoadrenalism is made by assessing the response to CRH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26311?source=see_link\">",
"     \"Corticotropin-releasing hormone stimulation test\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Possible adrenal crisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is essential that treatment of patients who present in possible adrenal crisis not be delayed while diagnostic tests are performed. Blood for serum cortisol and serum chemistry should be drawn and therapy initiated immediately with intravenous saline and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of adrenal insufficiency in adults\", section on 'Adrenal crisis'",
"    </a>",
"    .) The short",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24902?source=see_link\">",
"     ACTH stimulation test",
"    </a>",
"    can be performed after initiation of glucocorticoid treatment provided that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoid therapy has not been given for more than a few days, after which it could begin to suppress the hypothalamic-pituitary-adrenal axis and compromise the adrenal response.",
"     </li>",
"     <li>",
"      Neither",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      (cortisol) nor cortisone (which is converted to cortisol by the liver) is given because both are measured in cortisol radioimmunoassays.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       Dexamethasone",
"      </a>",
"      , which is not measured in these assays, is the glucocorticoid of choice in these patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ACTH STIMULATION TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several protocols have been used to assess the response to exogenous ACTH. The agent used is synthetic ACTH(1-24) (cosyntropin), which has the full biologic potency of native ACTH(1-39). Short (one hour or less) tests involve administration of a single-dose in a \"low\" or \"high\" concentration and can be performed on an outpatient basis. Both tests result in supraphysiological plasma ACTH concentrations: about 60,000",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (1320",
"    <span class=\"nowrap\">",
"     pmol/L)",
"    </span>",
"    after the standard high-dose ACTH test and about 1900",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (41.8",
"    <span class=\"nowrap\">",
"     pmol/L)",
"    </span>",
"    after the low-dose test [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/4\">",
"     4",
"    </a>",
"    ]. There are no untoward side effects. Allergic reactions are almost unheard of with cosyntropin. Prolonged ACTH stimulation tests are seldom performed because measurements of plasma ACTH in conjunction with the low-dose ACTH test provide the necessary information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Standard high-dose ACTH stimulation test",
"    </span>",
"    &nbsp;&mdash;&nbsp;This test consists of measuring serum cortisol immediately before and 30 and 60 minutes after intravenous injection of 250 mcg (85 nmol, or 40 international units) of cosyntropin, which represents the entire contents of the vial. This dose of cosyntropin results in pharmacological plasma ACTH concentrations for the 60-minute duration of the test.",
"   </p>",
"   <p>",
"    The advantage of the high-dose test is that the cosyntropin can be injected intramuscularly (IM), because pharmacologic plasma ACTH concentrations are still achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/5\">",
"     5",
"    </a>",
"    ]. The low-dose test has not been evaluated after IM injection and may not provide valid results by this route.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Low-dose ACTH stimulation test",
"    </span>",
"    &nbsp;&mdash;&nbsp;A test involving more physiological plasma concentrations of ACTH theoretically provides a more sensitive index of adrenocortical responsiveness. The low-dose ACTH test is performed by measuring serum cortisol immediately before and 30 minutes after intravenous injection of cosyntropin (synthetic ACTH(1-24)) in a dose either of 1",
"    <strong>",
"     mcg",
"    </strong>",
"    (160 milli-international units) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/6\">",
"     6",
"    </a>",
"    ] or of 0.5 mcg (80 milli-international units) per 1.73 m2 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 0.5 mcg per 1.73 m2 dose has the advantage of compensating for plasma volume, but it is about one-half the 1 mcg dose in most patients and may not result in the same peak serum cortisol concentrations at 30 minutes because the peak tends to be reached earlier and is 30 percent lower than after insulin-induced hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Furthermore, doses of 0.6 mcg and 0.8 mcg resulted in significantly lower responses than 1 mcg [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because a dose of 1",
"    <span class=\"nowrap\">",
"     mcg/1.73",
"    </span>",
"    m2 has not been studied in patients whose surface area varied significantly from 1.73 m2, it should be used with caution in such patients. Because it may lead to lower peak cortisol values, a normal result can be interpreted with confidence. By contrast a subnormal response may result if the ACTH dose is insufficient.",
"   </p>",
"   <p>",
"    Plasma ACTH can also be measured in the basal sample, as in all ACTH stimulation tests. In healthy individuals, cortisol responses are greatest in the morning, but in patients with adrenal insufficiency, the response to cosyntropin is the same in the morning and afternoon [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/11\">",
"     11",
"    </a>",
"    ]. Thus, we recommend that the test be done in the morning to minimize the risk of misdiagnosis in a normal individual. This dose stimulates maximal adrenocortical secretion up to 30 minutes post-injection and in normal subjects results in a peak plasma ACTH concentration about twice that of insulin-induced hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no commercially available preparation of \"low dose\" cosyntropin. One prepares the low-dose solution of cosyntropin locally; the vials of cosyntropin currently available contain 250 mcg and come with sterile normal saline solution to be used as diluent. Instructions are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inject 1 mL of the diluent into the vial of cosyntropin to produce a 250",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      solution and shake thoroughly.",
"     </li>",
"     <li>",
"      Using a 1 mL tuberculin syringe, withdraw 0.2 mL (ie, 50 mcg cosyntropin) and inject it into a vial containing 24.8 mL of sterile normal saline solution to produce a 2",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      solution.",
"     </li>",
"     <li>",
"      After shaking thoroughly, again using a 1 mL syringe, withdraw 0.5 mL (1 mcg cosyntropin) or the appropriate volume for the patient's surface area, and inject the entire volume immediately intravenously.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Eight-hour ACTH stimulation test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The eight-hour test, which is now rarely performed, consists of infusing 250 mcg (40 international units) of cosyntropin continuously over eight hours in 500 mL of isotonic saline. A 24-hour urine specimen is collected the day before and the day of the infusion for cortisol or 17-hydroxycorticoid (17-OHCS) and creatinine determination, and serum cortisol is determined at the end of the infusion. Plasma ACTH concentrations are supraphysiologic throughout the infusion.",
"   </p>",
"   <p>",
"    The infusion solution must contain isotonic saline (154",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    NaCl) because patients with adrenal insufficiency, who may already be hyponatremic and lack aldosterone, can become severely hyponatremic if given hypotonic solutions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25876?source=see_link\">",
"     \"Hyponatremia and hyperkalemia in adrenal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Two-day ACTH infusion test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two-day ACTH infusion test is similar to the eight-hour infusion test, except that the same dose of ACTH is infused for eight hours on two consecutive days [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/12\">",
"     12",
"    </a>",
"    ]. Daily 1 mg intramuscular injections of long-acting ACTH(1-18)-NH2 can be used outside the United States.",
"   </p>",
"   <p>",
"    This test may be helpful in distinguishing secondary from tertiary adrenal insufficiency (see below). The one-day eight-hour test is too short for this purpose, while longer tests add little further useful information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     NORMAL VALUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The current criteria used to indicate normal adrenal function are a minimum serum cortisol concentration &ge;18 to 20",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (500 to 550",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    before",
"    <strong>",
"     or",
"    </strong>",
"    after ACTH injection as described for each test below.",
"   </p>",
"   <p>",
"    Previous criteria that required a minimum increment in serum cortisol (eg, 3.3",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [90",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/6\">",
"     6",
"    </a>",
"    ] are invalid [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/13\">",
"     13",
"    </a>",
"    ], because individuals who have a high basal serum cortisol concentration, due either to normal circadian rhythmicity or acute stress, may be nearly maximally stimulated and unable to increase cortisol secretion further. In addition, approximately 20 percent of normal subjects with high-normal basal serum cortisol concentration have little or no rise after ACTH. It is therefore important to obtain both baseline and post-ACTH cortisol samples for accurate assessment of adrenal function.",
"   </p>",
"   <p>",
"    Furthermore, individuals may meet criteria for serum cortisol increment (eg, 3.3",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [90",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    with absolute values that clearly indicate adrenal insufficiency. As an example, an increase from 2",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (55",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    to 5.3",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (145",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    would not indicate that the patient had normal hypothalamic-pituitary-adrenal function, nor would an increase from 20",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (550",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    to 22",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (607",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    an increment of only 2",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (55",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    indicate that the patient had adrenal insufficiency.",
"   </p>",
"   <p>",
"    Some studies have used higher cutoff points (minimum serum cortisol 21.7 to 25.4",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [600 to 700",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    for the diagnosis of adrenal insufficiency, based upon results in patients known to have an abnormal response to insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/14\">",
"     14",
"    </a>",
"    ]. However, these are not clinically useful criteria, as up to 43 percent of normal individuals would be diagnosed as having adrenal insufficiency when these criteria are used [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cortisol assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variability in cortisol assays creates an additional problem with setting criteria for a normal response to ACTH that apply to all centers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/9,16-18\">",
"     9,16-18",
"    </a>",
"    ]. Two studies comparing cortisol results obtained with different assays showed a positive bias of radioimmunoassays and immunofluorometric enzyme assays of 10 to 50 percent compared with a reference value obtained using isotope dilution gas chromatography-mass spectrometry [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/9,16\">",
"     9,16",
"    </a>",
"    ]. As a result, in one study, depending on the combination of assay and criterion used, between 0 and 100 percent of healthy volunteers would be considered to have a normal response to ACTH [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/17\">",
"     17",
"    </a>",
"    ]. This illustrates the difficulty of interpreting cortisol responses that are close to the cutoff point. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/132?source=see_link\">",
"     \"Measurement of cortisol in serum and saliva\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Effect of oral contraceptives",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women, the response to ACTH is affected by the use of oral contraceptives (OCs), which increase cortisol binding globulin (CBG) levels. In one study evaluating the normal response to ACTH in 100 healthy adults (50 men and 50 women) and 13 women taking OCs, 30 minute total cortisol values were two-fold higher, and free cortisol values were lower in the OC group compared to controls [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/18\">",
"     18",
"    </a>",
"    ]. Therefore, OCs should be discontinued prior to testing to avoid underestimating hypocortisolism in these patients. Ideally, CBG levels should be measured and the test performed when the value is in the normal range.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Standard ACTH stimulation test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The criteria for serum cortisol on the standard high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24902?source=see_link\">",
"     ACTH stimulation test",
"    </a>",
"    is a minimum value 18 to 20",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (500 to 550",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    before",
"    <strong>",
"     or",
"    </strong>",
"    after ACTH injection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. A lower cutoff is used (&ge;16",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [440",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    if ACTH is administered intramuscularly rather than intravenously [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Salivary cortisol can also be measured during this test. Salivary cortisol increases to 19 &plusmn; 0.8",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (52 &plusmn; 2.2",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    (range: 8.7 to 36",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [24 to 99",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    one hour after injection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/132?source=see_link\">",
"     \"Measurement of cortisol in serum and saliva\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Low dose ACTH test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The criteria for serum cortisol is a minimum value &ge;18",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (500",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    before or after ACTH injection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Eight-hour ACTH stimulation test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 24-hour urinary excretion of 17-OHCS should increase three- to fivefold over baseline on the day of ACTH infusion. Serum cortisol should reach 20",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (550",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    in 30 to 60 minutes after the infusion is begun and exceed 25",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    (690",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    after six to eight hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Two-day ACTH stimulation test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary excretion of 17-OHCS should exceed 27 mg (74 nmol) during the first 24 hours of infusion and 47 mg (130 nmol) during the second 48 hours. Serum cortisol should reach 20",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    (550",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    in 30 to 60 minutes after the ACTH infusion is begun and exceed 25",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    (690",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    after six to eight hours. Both serum and urinary steroid values increase progressively thereafter, but the ranges of normal are not well-defined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     INTERPRETATION OF THE SERUM CORTISOL RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to ACTH varies with the underlying disorder.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient has hypopituitarism with deficient ACTH secretion and secondary adrenal insufficiency, then the intrinsically normal adrenal gland should respond to maximally stimulating concentrations of exogenous ACTH if given for a long enough time. The response may be less than in normal subjects and initially sluggish due to adrenal atrophy resulting from chronically low stimulation by endogenous ACTH.",
"     </li>",
"     <li>",
"      If, on the other hand, the patient has primary adrenal insufficiency, endogenous ACTH secretion is already elevated and there should be little or no adrenal response to exogenous ACTH.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, a clearly subnormal response to the low-dose or high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24902?source=see_link\">",
"     ACTH stimulation test",
"    </a>",
"    is diagnostic of primary or secondary adrenal insufficiency, whereas a normal response excludes both disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/20\">",
"     20",
"    </a>",
"    ]. Cortisol values between 18 to 25.4",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (500 to 700",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    represent a range of uncertainty in which patients may have discordant responses to ACTH, insulin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    . Higher concentrations represent a normal response in the non-ICU setting.",
"   </p>",
"   <p>",
"    There is controversy regarding whether the low-dose test is superior to the high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24902?source=see_link\">",
"     ACTH stimulation test",
"    </a>",
"    . A meta-analysis including 1021 patients studied with the high-dose test and 402 patients with the low-dose test found similar sensitivities, 57 percent and 61 percent, respectively, for the diagnosis of secondary adrenal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/21\">",
"     21",
"    </a>",
"    ]. The positive and negative likelihood ratios had overlapping confidence intervals, further suggesting that the two tests perform similarly. This information conflicts with earlier smaller studies suggesting that the low-dose test is more sensitive [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/1,22-24\">",
"     1,22-24",
"    </a>",
"    ]. The low-dose test can detect partial adrenal insufficiency (as can occur with the chronic use of inhaled glucocorticoids or early adrenal destruction by infectious or autoimmune disease) that may be missed by the standard high-dose test, which provides a supraphysiologic stimulus that can stimulate a partially diseased adrenal [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/8,25\">",
"     8,25",
"    </a>",
"    ]. It is possible that differences in the study populations or cortisol assays and criteria for interpretation may account for these differences. Further studies are needed to determine whether the low-dose test is preferable in specific clinical circumstances.",
"   </p>",
"   <p>",
"    Data indicate that the low-dose test (like the 250 mcg test) is not valid if there has been recent pituitary injury, and supports the conclusion that a 30-minute serum cortisol concentration less than 18",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (500",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    indicates impaired adrenocortical reserve [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/26\">",
"     26",
"    </a>",
"    ]. We believe this is the most conservative current criterion and recommend its use until more data on the 1 mcg ACTH test become available.",
"   </p>",
"   <p>",
"    The low-dose test does not reliably indicate HPA axis suppression in preterm infants whose mothers received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    for less than two weeks before delivery to hasten fetal lung development [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/27\">",
"     27",
"    </a>",
"    ]. The CRH test should be used in this situation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PRIMARY VERSUS PITUITARY OR HYPOTHALAMIC HYPOADRENALISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;An inadequate serum cortisol response to ACTH stimulation establishes the diagnosis of adrenal insufficiency but does not distinguish between the primary and secondary forms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3880?source=see_link\">",
"     \"Causes of secondary and tertiary adrenal insufficiency in adults\"",
"    </a>",
"    .) There are two ways to distinguish among them:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurement of plasma ACTH in the basal sample. If it is higher than normal, the patient has primary adrenal insufficiency, whereas if it is low, the diagnosis is secondary or tertiary adrenal insufficiency.",
"     </li>",
"     <li>",
"      Measurement of the response of serum cortisol to prolonged ACTH stimulation. In primary adrenal insufficiency, prolonged stimulation results in little, if any, increase in cortisol production. In secondary adrenal insufficiency, on the other hand, the adrenal gland is intrinsically normal but is atrophic because of chronic ACTH deficiency. In most of these patients, stimulation for one day (eight hours) is too brief to exert a major effect. Continuous infusion of ACTH for two days results in an increase in 24-hour urinary 17-OHCS excretion to 9 mg (25 nmol) or more during the second day of infusion in most patients with hypopituitarism. Occasional patients may require three to five days of stimulation. However, even after five days, serum cortisol concentrations may not attain those reached after one to eight hours of ACTH stimulation in normal subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/28\">",
"       28",
"      </a>",
"      ], and 24-hour urinary 17-OHCS may increase only threefold over baseline [",
"      <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With the availability of accurate measurements of basal plasma ACTH, prolonged ACTH infusion tests have become unnecessary for determining the cause of adrenal insufficiency and should be considered as confirmatory tests only in patients with equivocal plasma ACTH values.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     STRESS AND SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An area in which there continues to be controversy is whether the high-dose ACTH test accurately predicts the ability of a patient to respond adequately to stress, such as major surgery. The controversy is based upon the observation that occasional patients have normal responses to cosyntropin, but subnormal responses to insulin-induced hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/30,31\">",
"     30,31",
"    </a>",
"    ], although the hypoglycemia has not always been adequate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical importance of these discrepant results is uncertain. Rare patients who respond normally to the high-dose ACTH test have a subnormal serum cortisol response to surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/13\">",
"     13",
"    </a>",
"    ]; however, these patients tolerate surgery normally [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/32\">",
"     32",
"    </a>",
"    ]. Furthermore, the serum cortisol responses of most patients to the high-dose ACTH test and to insulin-induced hypoglycemia are very similar [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/31\">",
"     31",
"    </a>",
"    ]. The presumed reason is that the endogenous ACTH secretion elicited in response to insulin-induced hypoglycemia is maximally stimulating during the hour or less that the test lasts, as are the plasma concentrations of exogenous ACTH achieved during the high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24902?source=see_link\">",
"     ACTH stimulation test",
"    </a>",
"    . In contrast, the plasma ACTH concentrations achieved in the low-dose ACTH test are not maximally stimulating [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/1,8\">",
"     1,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In all three tests, a normal serum cortisol response is predicated upon the fact that the adrenal gland has been stimulated with sufficient endogenous ACTH each day to prevent adrenal atrophy and maintain the basal activity of the steroidogenic enzymes. The reason patients do well during major surgery, even though their serum cortisol concentrations may not rise normally in response to ACTH or the surgery, may be that more than basal daily cortisol secretion is not needed to survive surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Recent ACTH deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outside of the critical care setting, with one exception, any patient who responds normally to the high-dose ACTH test does not require glucocorticoid supplementation for stress, surgical or otherwise. The exception is the patient who is acutely ACTH-deficient, as might occur soon after pituitary surgery or brain or pituitary stalk trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During the several days after cessation of ACTH secretion, the zonae fasciculata and reticularis of the adrenals undergo functional and anatomical atrophy. However, during part of that interval the adrenals may respond normally to pharmacological doses of ACTH, whereas the pituitary gland is unable to release ACTH in response to stress. Therefore, these patients will respond normally to the high-dose ACTH test, but fail to respond to insulin-induced hypoglycemia (since they cannot increase ACTH secretion). Such patients, who can usually be identified by their history, require glucocorticoid supplementation during surgical or other stresses.",
"   </p>",
"   <p>",
"    In patients who have undergone pituitary surgery, the cortisol response to standard-dose ACTH testing correlates well with the results of an insulin-induced hypoglycemia test if performed at least four weeks after surgery. In a study of 41 patients who were evaluated using standard-dose ACTH and insulin-induced hypoglycemia testing at one and four to six weeks after pituitary surgery (Cushing's disease excluded), all patients with a 30-minute serum cortisol after a standard-dose ACTH test of less than 12.7",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (350",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    four to six weeks post-op had a subnormal response to hypoglycemia, while those with a serum cortisol greater than 23.6",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (650",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    had a normal response to hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/34\">",
"     34",
"    </a>",
"    ]. Patients with intermediate values required additional testing to determine whether they had adrenal insufficiency.",
"   </p>",
"   <p>",
"    Some [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/1,6,8,22,26,35-37\">",
"     1,6,8,22,26,35-37",
"    </a>",
"    ], but not all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/21,38,39\">",
"     21,38,39",
"    </a>",
"    ] have reported that patients with mild or recent secondary or tertiary adrenal insufficiency are more likely to have a subnormal cortisol response on a low-dose test than the high-dose ACTH test. In a study of children with multiple pituitary deficiencies, both ACTH tests were equivalent to the insulin-induced hypoglycemia test, but this study did not include patients with ACTH deficiency of brief duration [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The issue is not whether patients with mild or recent secondary or tertiary adrenal insufficiency will have normal ACTH and cortisol responses during stress [",
"      <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/41\">",
"       41",
"      </a>",
"      ]; the issue is whether patients who respond normally to the low-dose ACTH test (or any other test) are at any greater risk for adverse effects of adrenal insufficiency during stress than a patient with perfectly normal hypothalamic-pituitary-adrenal function.",
"     </li>",
"     <li>",
"      Until this issue is resolved, patients with possible acute ACTH deficiency, even if they have a normal response to ACTH, should be given glucocorticoid and saline during major stress or surgery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link\">",
"       \"Treatment of adrenal insufficiency in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CRITICAL ILLNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subnormal corticosteroid production during critical illness in the absence of structural defects in the hypothalamic-pituitary-adrenal axis has been termed \"functional adrenal insufficiency\" or \"relative adrenal insufficiency\" [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/42\">",
"     42",
"    </a>",
"    ]. Critically ill patients with a high basal cortisol level may not show a further increase after ACTH administration [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. In three studies, either a basal cortisol level of &lt;20, 25 or 30",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (550, 690, 825",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    or an incremental response of less than 9",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (250",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    after cosyntropin stimulation predicted a poor outcome and identified patients who responded favorably to glucocorticoid administration in terms of earlier ventilator weaning and improved mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/44-47\">",
"     44-47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, use of the incremental response has been challenged in this setting as well, because individuals who are maximally stimulated by endogenous stress may not show a further increase in cortisol. In one retrospective study of 71 patients, the peak response to cosyntropin, 1 mcg, but not the increment in cortisol, correlated best with the hemodynamic response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    therapy. These authors suggest use of this test, with a peak serum cortisol response of &lt;25.4",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (700 nmol) to make the diagnosis of adrenal insufficiency in the critical care unit [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, interpretation of serum total cortisol concentrations may be misleading in the presence of decreased amounts of cortisol-binding proteins. As an example, in a study of 66 critically ill patients, 36 of whom had hypoproteinemia (albumin concentration &lt;2.5",
"    <span class=\"nowrap\">",
"     g/dL),",
"    </span>",
"    the following results were seen [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Baseline and ACTH-stimulated total cortisol concentrations were lower in the patients with hypoproteinemia than in those with serum albumin &gt;2.5",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"     </li>",
"     <li>",
"      In contrast, baseline serum free cortisol concentrations were similar in the two groups (5.1 &plusmn; 4.2 and 5.2 &plusmn; 3.5",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      [140.7 and 143.5",
"      <span class=\"nowrap\">",
"       nmol/L]).",
"      </span>",
"     </li>",
"     <li>",
"      In 14 patients (all of whom were hypoproteinemic), ACTH-stimulated serum total cortisol concentrations were suggestive of functional adrenal insufficiency (&le;18.5",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      [510.4",
"      <span class=\"nowrap\">",
"       nmol/L]).",
"      </span>",
"     </li>",
"     <li>",
"      In all 66 patients, including the 14 with subnormal stimulated total cortisol values, both baseline and ACTH-stimulated serum free cortisol concentrations were high-normal or elevated when compared with a group of 33 healthy volunteers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, while glucocorticoid secretion increases during critical illness, the increase may not be detected if only total cortisol concentrations are measured. Serum free cortisol measurements may be helpful to avoid unnecessary glucocorticoid therapy, but these assays are not yet widely available.",
"   </p>",
"   <p>",
"    In summary, while some critically ill patients may have functional adrenal insufficiency, there is currently no consensus on diagnostic criteria or indications for treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/42\">",
"     42",
"    </a>",
"    ]. Further studies are needed to clarify this controversial area. The diagnosis and management of functional adrenal insufficiency is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16281?source=see_link\">",
"     \"Corticosteroid therapy in septic shock\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     CONGENITAL ADRENAL HYPERPLASIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the evaluation of patients with hirsutism, the possibility of mild CYP21A2 (P-450c21, 21-hydroxylase) deficiency must be considered. The incidence of the classical form in the general population, as estimated from neonatal screening studies, is very low (1 in 5000 to 15,000) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/50,51\">",
"     50,51",
"    </a>",
"    ] compared with one in 700 in unique groups such as Yupik Eskimos [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. The nonclassical form, however, occurs in about 1 in 300 people in the general white population and in about 1 in 30 Jews of European origin [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/54\">",
"     54",
"    </a>",
"    ]. In some patients, basal serum adrenal androgen concentrations are within the normal range, but the defect can be unmasked by acutely stimulating the adrenal cortex with ACTH and measuring serum 17-hydroxyprogesterone. The high-dose ACTH test is conducted as described above, except that blood is sampled immediately before and 30 to 60 minutes after the injection of cosyntropin for measurement of serum 17-hydroxyprogesterone.",
"   </p>",
"   <p>",
"    Basal and stimulated serum 17-hydroxyprogesterone concentrations are compared with those of normal subjects. Patients whose concentrations exceed normal may be considered to have mild \"adult-onset\" CYP21A2 deficiency. Some investigators estimate its incidence may be as high as 12 percent in hirsute women, but in our experience and that of others the incidence appears to be far lower. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/28/24007?source=see_link\">",
"     \"Pathogenesis and causes of hirsutism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a linear relationship between basal and stimulated serum 17-hydroxyprogesterone concentrations. Thus, basal values should theoretically be as useful as stimulated ones for establishing this diagnosis. Basal values may be only slightly elevated, especially late in the day, but are always greater than 200",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (6",
"    <span class=\"nowrap\">",
"     nmol/L).",
"    </span>",
"    ACTH-stimulated values are greater than 1500",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (43",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Heterozygotes have smaller responses that may overlap the responses of normal subjects and, occasionally, those of homozygotes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24726?source=see_link\">",
"     \"Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with ambiguous genitalia, premature pubarche or hirsutism, evaluation for possible 3-beta-hydroxysteroid dehydrogenase deficiency should include a standard",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24902?source=see_link\">",
"     ACTH stimulation test",
"    </a>",
"    . Responses vary with age. Neonates have peak ACTH-stimulated serum delta-5-17-hydroxypregnenolone concentrations of 12,600",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (378",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    or more. Peak values in Tanner stage I children are 5490",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (165",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    or more, they are 9790",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (294",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    or more in children with premature pubarche, and they are 9620",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (289",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    or more in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/59\">",
"     59",
"    </a>",
"    ]. Adult hirsute women with a normal 3-beta-hydroxysteroid dehydrogenase genotype may have stimulated serum delta-5-17-hydroxypregnenolone concentrations up to 5000",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (150",
"    <span class=\"nowrap\">",
"     nmol/L).",
"    </span>",
"    Most women previously considered to have the late-onset or nonclassic form of 3-beta-hydroxysteroid dehydrogenase deficiency do not have the disorder, based on this criterion.",
"   </p>",
"   <p>",
"    Exaggerated 17-hydroxyprogesterone responses are also seen in almost 60 percent of patients with unilateral adrenal incidentalomas, and even more of those with bilateral masses [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     CUSHING'S SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24902?source=see_link\">",
"     ACTH stimulation test",
"    </a>",
"    has little or no place in the evaluation of patients with Cushing's syndrome because it does not help in either making the diagnosis or determining the cause of the hypercortisolemia. Patients with Cushing's disease respond because they have bilateral adrenocortical hyperplasia. About half of patients with Cushing's syndrome due to adrenal adenomas respond, but those due to carcinomas almost never do [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24905/abstract/60\">",
"     60",
"    </a>",
"    ]. The normal adrenals of patients with nonfunctioning carcinomas may respond normally to ACTH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10271581\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The low-dose and high-dose ACTH stimulation tests have supplanted insulin-induced hypoglycemia to evaluate hypothalamic-pituitary adrenal function. The results are similar to those obtained with insulin-induced hypoglycemia; ACTH tests can be performed without the presence of a clinician and are less expensive.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24902?source=see_link\">",
"       ACTH stimulation test",
"      </a>",
"      is intermediate in sensitivity between the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"       metyrapone",
"      </a>",
"      test and the insulin-induced hypoglycemia or high dose ACTH stimulation test. It may detect more subtle deficiency in cortisol secretion than high dose ACTH, but the clinical importance of this finding is uncertain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Indications for testing HPA axis",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dynamic testing should be performed to establish the diagnosis in patients with equivocal serum cortisol values in whom hypoadrenalism is suspected. With simultaneous measurement of the plasma ACTH, it is possible to distinguish between primary and secondary or tertiary adrenal insufficiency. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for dynamic testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     ACTH stimulation tests",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ACTH (1-24) (cosyntropin), which has the full biologic potency of native ACTH (1-39), is used to perform these tests. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'ACTH stimulation tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A standard high dose test consists of measuring serum cortisol before, 30 and 60 minutes after IV injection of 250 mcg of cosyntropin; at this high dose, it can also be injected intramuscularly (IM). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'ACTH stimulation tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The low-dose ACTH test is performed by measuring serum cortisol before and 30 minutes after IV injection of 1 mcg cosyntropin. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'ACTH stimulation tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The current criteria used to indicate normal adrenal function are a minimum serum cortisol concentration &ge;18 (low dose test) or 18 to 20 (high-dose test)",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (500 to 550",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      before",
"      <strong>",
"       or",
"      </strong>",
"      after cosyntropin injection. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Normal values'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A lower cutoff is used (&ge;16",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      [440",
"      <span class=\"nowrap\">",
"       nmol/L])",
"      </span>",
"      if high dose cosyntropin is administered intramuscularly. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Normal values'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High CBG levels in women using oral contraceptives may falsify interpretation of ACTH test; they should be discontinued prior to testing to avoid underestimating hypocortisolism in these patients. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Effect of oral contraceptives'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ACTH stimulation tests are not valid to evaluate HPA function if there has been a recent pituitary injury and insulin-induced hypoglycemia should be used in these circumstances.",
"     </li>",
"     <li>",
"      Simultaneous determination of basal ACTH before performing the cortrosyn stimulation test allows to determine if adrenal insufficiency is a primary adrenal disease (elevated basal ACTH values) or secondary to hypothalamic-pituitary deficiency (low basal ACTH value). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Primary versus pituitary or hypothalamic hypoadrenalism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In critically ill patients there may functional adrenal insufficiency, but interpretation of ACTH stimulation tests are difficult when using total cortisol assays in blood as these patients have important decreases in CBG levels and assays for free cortisol levels are not usually available; there is currently no consensus on diagnostic criteria or indications for treatment in such patient population. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Critical illness'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/1\">",
"      Tordjman K, Jaffe A, Grazas N, et al. The role of the low dose (1 microgram) adrenocorticotropin test in the evaluation of patients with pituitary diseases. J Clin Endocrinol Metab 1995; 80:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/2\">",
"      H&auml;gg E, Asplund K, Lithner F. Value of basal plasma cortisol assays in the assessment of pituitary-adrenal insufficiency. Clin Endocrinol (Oxf) 1987; 26:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/3\">",
"      JENKINS D, FORSHAM PH, LAIDLAW JC, et al. Use of ACTH in the diagnosis of adrenal cortical insufficiency. Am J Med 1955; 18:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/4\">",
"      Tordjman K, Jaffe A, Greenman Y, Stern N. Comments on the comparison of low and high dose corticotropin stimulation tests in patients with pituitary disease. J Clin Endocrinol Metab 1998; 83:4530; author reply 4532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/5\">",
"      Longui CA, Vottero A, Harris AG, Chrousos GP. Plasma cortisol responses after intramuscular corticotropin 1-24 in healthy men. Metabolism 1998; 47:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/6\">",
"      Dickstein G, Shechner C, Nicholson WE, et al. Adrenocorticotropin stimulation test: effects of basal cortisol level, time of day, and suggested new sensitive low dose test. J Clin Endocrinol Metab 1991; 72:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/7\">",
"      Crowley S, Hindmarsh PC, Holownia P, et al. The use of low doses of ACTH in the investigation of adrenal function in man. J Endocrinol 1991; 130:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/8\">",
"      Broide J, Soferman R, Kivity S, et al. Low-dose adrenocorticotropin test reveals impaired adrenal function in patients taking inhaled corticosteroids. J Clin Endocrinol Metab 1995; 80:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/9\">",
"      Nye EJ, Grice JE, Hockings GI, et al. Comparison of adrenocorticotropin (ACTH) stimulation tests and insulin hypoglycemia in normal humans: low dose, standard high dose, and 8-hour ACTH-(1-24) infusion tests. J Clin Endocrinol Metab 1999; 84:3648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/10\">",
"      Dickstein G, Spigel D, Arad E, Shechner C. One microgram is the lowest ACTH dose to cause a maximal cortisol response. There is no diurnal variation of cortisol response to submaximal ACTH stimulation. Eur J Endocrinol 1997; 137:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/11\">",
"      Park YJ, Park KS, Kim JH, et al. Reproducibility of the cortisol response to stimulation with the low dose (1 microg) of ACTH. Clin Endocrinol (Oxf) 1999; 51:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/12\">",
"      Rose LI, Williams GH, Jagger PI, Lauler DP. The 48-hour adrenocorticotrophin infusion test for adrenocortical insufficiency. Ann Intern Med 1970; 73:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/13\">",
"      Kehlet H, Binder C. Value of an ACTH test in assessing hypothalamic-pituitary-adrenocortical function in glucocorticoid-treated patients. Br Med J 1973; 2:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/14\">",
"      Tordjman K, Jaffe A, Greenman Y, Stern N. Comments on the comparison of low and high dose corticotropin stimulation tests in patients with pituitary disease. J Clin Endocrinol Metab 1998; 83:4530; author reply 4532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/15\">",
"      Laudat MH, Cerdas S, Fournier C, et al. Salivary cortisol measurement: a practical approach to assess pituitary-adrenal function. J Clin Endocrinol Metab 1988; 66:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/16\">",
"      De Brabandere VI, Thienpont LM, St&ouml;ckl D, De Leenheer AP. Three routine methods for serum cortisol evaluated by comparison with an isotope dilution gas chromatography-mass spectrometry method. Clin Chem 1995; 41:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/17\">",
"      Nieman LK. Dynamic evaluation of adrenal hypofunction. J Endocrinol Invest 2003; 26:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/18\">",
"      Klose M, Lange M, Rasmussen AK, et al. Factors influencing the adrenocorticotropin test: role of contemporary cortisol assays, body composition, and oral contraceptive agents. J Clin Endocrinol Metab 2007; 92:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/19\">",
"      May ME, Carey RM. Rapid adrenocorticotropic hormone test in practice. Retrospective review. Am J Med 1985; 79:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/20\">",
"      Speckart PF, Nicoloff JT, Bethune JE. Screening for adrenocortical insufficiency with cosyntropin (synthetic ACTH). Arch Intern Med 1971; 128:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/21\">",
"      Dorin RI, Qualls CR, Crapo LM. Diagnosis of adrenal insufficiency. Ann Intern Med 2003; 139:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/22\">",
"      Abdu TA, Elhadd TA, Neary R, Clayton RN. Comparison of the low dose short synacthen test (1 microg), the conventional dose short synacthen test (250 microg), and the insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in patients with pituitary disease. J Clin Endocrinol Metab 1999; 84:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/23\">",
"      Zarkovi M, Ciri J, Stojanovi M, et al. Optimizing the diagnostic criteria for standard (250-microg) and low dose (1-microg) adrenocorticotropin tests in the assessment of adrenal function. J Clin Endocrinol Metab 1999; 84:3170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/24\">",
"      Dickstein G. Commentary to the article: comparison of low and high dose corticotropin stimulation tests in patients with pituitary disease. J Clin Endocrinol Metab 1998; 83:4531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/25\">",
"      Streeten DH, Anderson GH Jr, Bonaventura MM. The potential for serious consequences from misinterpreting normal responses to the rapid adrenocorticotropin test. J Clin Endocrinol Metab 1996; 81:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/26\">",
"      Thaler LM, Blevins LS Jr. The low dose (1-microg) adrenocorticotropin stimulation test in the evaluation of patients with suspected central adrenal insufficiency. J Clin Endocrinol Metab 1998; 83:2726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/27\">",
"      Karlsson R, Kallio J, Irjala K, et al. Adrenocorticotropin and corticotropin-releasing hormone tests in preterm infants. J Clin Endocrinol Metab 2000; 85:4592.",
"     </a>",
"    </li>",
"    <li>",
"     Cope CL. Adrenal Steroids and Disease, Pittman Medical, London 1972.",
"    </li>",
"    <li>",
"     Thorn GW. Adrenal cortical insufficiency. In: Current Diagnosis, Conn HF, Clohecy RJ, Conn RB (Eds), WB Saunders, Philadelphia 1966. p.445.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/30\">",
"      Lindholm J, Kehlet H. Re-evaluation of the clinical value of the 30 min ACTH test in assessing the hypothalamic-pituitary-adrenocortical function. Clin Endocrinol (Oxf) 1987; 26:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/31\">",
"      Borst GC, Michenfelder HJ, O'Brian JT. Discordant cortisol response to exogenous ACTH and insulin-induced hypoglycemia in patients with pituitary disease. N Engl J Med 1982; 306:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/32\">",
"      Ritchie DM, Boyle JA, McInnes JM, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968; 37:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/33\">",
"      Udelsman R, Ramp J, Gallucci WT, et al. Adaptation during surgical stress. A reevaluation of the role of glucocorticoids. J Clin Invest 1986; 77:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/34\">",
"      Courtney CH, McAllister AS, Bell PM, et al. Low- and standard-dose corticotropin and insulin hypoglycemia testing in the assessment of hypothalamic-pituitary-adrenal function after pituitary surgery. J Clin Endocrinol Metab 2004; 89:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/35\">",
"      Rasmuson S, Olsson T, Hagg E. A low dose ACTH test to assess the function of the hypothalamic-pituitary-adrenal axis. Clin Endocrinol (Oxf) 1996; 44:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/36\">",
"      Talwar V, Lodha S, Dash RJ. Assessing the hypothalamo-pituitary-adrenocortical axis using physiological doses of adrenocorticotropic hormone. QJM 1998; 91:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/37\">",
"      D&ouml;kmeta HS, Colak R, Keletimur F, et al. A comparison between the 1-microg adrenocorticotropin (ACTH) test, the short ACTH (250 microg) test, and the insulin tolerance test in the assessment of hypothalamo-pituitary-adrenal axis immediately after pituitary surgery. J Clin Endocrinol Metab 2000; 85:3713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/38\">",
"      Mayenknecht J, Diederich S, B&auml;hr V, et al. Comparison of low and high dose corticotropin stimulation tests in patients with pituitary disease. J Clin Endocrinol Metab 1998; 83:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/39\">",
"      Suliman AM, Smith TP, Labib M, et al. The low-dose ACTH test does not provide a useful assessment of the hypothalamic-pituitary-adrenal axis in secondary adrenal insufficiency. Clin Endocrinol (Oxf) 2002; 56:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/40\">",
"      Weintrob N, Sprecher E, Josefsberg Z, et al. Standard and low-dose short adrenocorticotropin test compared with insulin-induced hypoglycemia for assessment of the hypothalamic-pituitary-adrenal axis in children with idiopathic multiple pituitary hormone deficiencies. J Clin Endocrinol Metab 1998; 83:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/41\">",
"      Streeten DH. Shortcomings in the low-dose (1 microg) ACTH test for the diagnosis of ACTH deficiency states. J Clin Endocrinol Metab 1999; 84:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/42\">",
"      Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003; 348:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/43\">",
"      Jurney TH, Cockrell JL Jr, Lindberg JS, et al. Spectrum of serum cortisol response to ACTH in ICU patients. Correlation with degree of illness and mortality. Chest 1987; 92:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/44\">",
"      Rivers EP, Gaspari M, Saad GA, et al. Adrenal insufficiency in high-risk surgical ICU patients. Chest 2001; 119:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/45\">",
"      Annane D, S&eacute;bille V, Troch&eacute; G, et al. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000; 283:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/46\">",
"      Marik PE, Zaloga GP. Adrenal insufficiency during septic shock. Crit Care Med 2003; 31:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/47\">",
"      Annane D, S&eacute;bille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/48\">",
"      Bourne RS, Webber SJ, Hutchinson SP. Adrenal axis testing and corticosteroid replacement therapy in septic shock patients--local and national perspectives. Anaesthesia 2003; 58:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/49\">",
"      Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. N Engl J Med 2004; 350:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/50\">",
"      Cacciari E, Balsamo A, Cassio A, et al. Neonatal screening for congenital adrenal hyperplasia. Arch Dis Child 1983; 58:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/51\">",
"      New MI. Steroid 21-hydroxylase deficiency (congenital adrenal hyperplasia). Am J Med 1995; 98:2S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/52\">",
"      Hirschfeld AJ, Fleshman JK. An unusually high incidence of salt-losing congenital adrenal hyperplasia in the Alaskan Eskimo. J Pediatr 1969; 75:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/53\">",
"      Pang S, Murphey W, Levine LS, et al. A pilot newborn screening for congenital adrenal hyperplasia in Alaska. J Clin Endocrinol Metab 1982; 55:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/54\">",
"      White PC, New MI, Dupont B. Congenital adrenal hyperplasia. (1). N Engl J Med 1987; 316:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/55\">",
"      White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000; 21:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/56\">",
"      Azziz R, Dewailly D, Owerbach D. Clinical review 56: Nonclassic adrenal hyperplasia: current concepts. J Clin Endocrinol Metab 1994; 78:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/57\">",
"      Gutai JP, Kowarski AA, Migeon CJ. The detection of the heterozygous carrier for congenital virilizing adrenal hyperplasia. J Pediatr 1977; 90:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/58\">",
"      Bachega TA, Brenlha EM, Billerbeck AE, et al. Variable ACTH-stimulated 17-hydroxyprogesterone values in 21-hydroxylase deficiency carriers are not related to the different CYP21 gene mutations. J Clin Endocrinol Metab 2002; 87:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/59\">",
"      Lutfallah C, Wang W, Mason JI, et al. Newly proposed hormonal criteria via genotypic proof for type II 3beta-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab 2002; 87:2611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24905/abstract/60\">",
"      Bertagna C, Orth DN. Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978). Am J Med 1981; 71:855.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 157 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-50E636C042-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_20_24905=[""].join("\n");
var outline_f24_20_24905=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10271581\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR DYNAMIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Possible adrenal crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ACTH STIMULATION TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Standard high-dose ACTH stimulation test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Low-dose ACTH stimulation test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Eight-hour ACTH stimulation test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Two-day ACTH infusion test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      NORMAL VALUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cortisol assays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Effect of oral contraceptives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Standard ACTH stimulation test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Low dose ACTH test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Eight-hour ACTH stimulation test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Two-day ACTH stimulation test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      INTERPRETATION OF THE SERUM CORTISOL RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PRIMARY VERSUS PITUITARY OR HYPOTHALAMIC HYPOADRENALISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      STRESS AND SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Recent ACTH deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CRITICAL ILLNESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      CONGENITAL ADRENAL HYPERPLASIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      CUSHING'S SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10271581\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3880?source=related_link\">",
"      Causes of secondary and tertiary adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16281?source=related_link\">",
"      Corticosteroid therapy in septic shock",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26311?source=related_link\">",
"      Corticotropin-releasing hormone stimulation test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44777?source=related_link\">",
"      Diagnosis of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24726?source=related_link\">",
"      Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25876?source=related_link\">",
"      Hyponatremia and hyperkalemia in adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/8/132?source=related_link\">",
"      Measurement of cortisol in serum and saliva",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/28/24007?source=related_link\">",
"      Pathogenesis and causes of hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_20_24906="Insulin therapy in adults with type 1 diabetes mellitus";
var content_f24_20_24906=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Insulin therapy in adults with type 1 diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/20/24906/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/20/24906/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/20/24906/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/20/24906/contributors\">",
"     Irl B Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/20/24906/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/20/24906/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/20/24906/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Diabetes Control and Complications Trial (DCCT) and other smaller studies demonstrated that improved glycemic control with intensive insulin therapy in patients with type 1 diabetes mellitus led to graded reductions in retinopathy, nephropathy, and neuropathy (",
"    <a class=\"graphic graphic_figure graphicRef61305 \" href=\"UTD.htm?28/32/29197\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef73143 \" href=\"UTD.htm?18/21/18781\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/1\">",
"     1",
"    </a>",
"    ]. The Epidemiology of Diabetes Interventions and Complications (EDIC) follow-up study from the DCCT demonstrated that intensive insulin therapy also reduces cardiovascular morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/2\">",
"     2",
"    </a>",
"    ]. What was considered \"intensive therapy\" in the DCCT is now considered to be standard therapy for management of type 1 diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=see_link\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues relevant to insulin therapy in patients with type 1 diabetes will be reviewed here. A review of its use in type 2 diabetes is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=see_link\">",
"     \"Insulin therapy in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A general discussion of management of type 1 diabetes in children and adolescents, intensive insulin therapy for critically ill patients (who are not necessarily diabetic), and interactive cases focusing on insulin therapy are also found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40090?source=see_link\">",
"     \"Management of type 1 diabetes mellitus in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=see_link\">",
"     \"Glycemic control and intensive insulin therapy in critical illness\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/48/5889?source=see_link\">",
"     \"Interactive diabetes case 1: Inpatient management in type 1 diabetes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/20/9538?source=see_link\">",
"     \"Interactive diabetes case 3: Hypoglycemia in a patient with type 1 diabetes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Optimal insulin therapy requires an understanding of insulin pharmacokinetics. A number of factors influence the pharmacokinetics of insulin, including: the insulin preparation, size of subcutaneous depot, injection technique, site of injection, alterations in subcutaneous blood flow and, potentially, the presence and titer of anti-insulin antibodies. These topics are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link\">",
"     \"General principles of insulin therapy in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRETREATMENT CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"conventional insulin therapy\" is used to describe simpler non-physiologic insulin regimens, such as single daily injections, or two injections per day (usually a combination of regular or short-acting and NPH insulins, mixed together in the same syringe and given in fixed amounts before breakfast and dinner). The term \"intensive insulin therapy\" describes treatment with three or more injections per day or with continuous subcutaneous insulin infusion with an insulin pump.",
"   </p>",
"   <p>",
"    Intensive therapy aims to provide a more physiologic profile of insulin by administration of a basal level of insulin (delivered by daily or twice daily injections of a long-acting insulin preparation, or continuous subcutaneous delivery of a rapid insulin preparation via a pump) and premeal boluses of a short or rapid-acting insulin. The dose of the pre-meal bolus is determined by the ambient blood glucose level before the meal, the size and composition of the meal, and anticipated activity levels.",
"   </p>",
"   <p>",
"    Intensive insulin therapy is recommended for the majority of patients with type 1 diabetes. However, it is important to emphasize that this regimen will be successful only if the patient is fully committed to it, has good understanding of the regimen, and is supported by a health care team with sufficient enthusiasm and expertise to educate the patient and to continuously monitor his or her progress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Drawbacks to intensive insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although intensive insulin therapy has clear benefits in patients with type 1 diabetes, it is important to consider the major drawbacks associated with this regimen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A greater effort is required by the patient to manage and coordinate diet, activity, insulin administration, and blood glucose monitoring. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=see_link\">",
"       \"Blood glucose self-monitoring in management of adults with diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The incidence of hypoglycemia may be increased up to threefold in patients with type 1 diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=see_link\">",
"       \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Weight gain is more likely, which can limit patient compliance, particularly in women. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Weight gain'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The cost of intensive insulin therapy ($4000 to",
"      <span class=\"nowrap\">",
"       $6000/year)",
"      </span>",
"      was about three times that of conventional treatment, based upon an analysis of the DCCT and costs from the early 1990s [",
"      <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In spite of these drawbacks, intensive insulin therapy is recommended for the majority of patients with type 1 diabetes to prevent, slow, or even reverse the development of complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     When to start intensive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies suggest that intensive therapy should be started as early as possible following the diagnosis of type 1 diabetes. In 303 patients from the DCCT with recent-onset type 1 diabetes and residual beta-cell function who were randomly assigned to intensive or conventional insulin therapy, those receiving intensive therapy were slower to lose residual beta-cell function than the conventional therapy group (risk reduction 57 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, intensive therapy in those with residual beta cell function resulted in a lower A1C, a 50 percent reduced risk for retinopathy progression, and a lower risk for severe hypoglycemia compared with those who received intensive therapy but did not have residual beta cell function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CHOICE OF INSULIN REGIMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic requirements of an optimal insulin regimen are a stable baseline dose of insulin (basal insulin; whether an intermediate or long-acting insulin injection or a short or rapid-acting insulin given via continuous subcutaneous insulin infusion) plus adjustable doses of pre-meal short-acting insulin (regular) or rapid-acting insulin analogs (lispro, aspart, or glulisine). The approximate time of onset, peak activity, and duration of action of the most commonly used insulins are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef73676 \" href=\"UTD.htm?1/62/2028\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link\">",
"     \"General principles of insulin therapy in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the DCCT, in which all supplies were free, patients in the intensive therapy group were allowed to choose between multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII) and could switch between the two during the study [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/1\">",
"     1",
"    </a>",
"    ]. Fifty-nine percent of the patients in the intensive therapy group used a pump at least part of the time; however, the pump was used for only 34 percent of the time during the study. Glycemic control, frequency of severe hypoglycemia, and progression of microvascular disease were similar with either type of insulin therapy.",
"   </p>",
"   <p>",
"    In meta-analyses of randomized controlled trials that compared continuous subcutaneous insulin with multiple daily injections (MDI), continuous therapy resulted in slightly better glycemic control (weighted mean difference -0.2 to -0.4 percentage points) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. Many of the trials included in the meta-analyses used rapid-acting insulin analogs instead of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    for CSII and rapid and long-acting insulin analogs for MDI. The impact on hypoglycemia was less certain. Although a 2009 meta-analysis showed a reduction in severe hypoglycemia with continuous insulin therapy compared with MDI, the analysis was limited by significant heterogeneity in the trial results [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Small trials comparing intensive insulin therapy using MDI versus CSII reported no difference in quality of life measures between treatment groups [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The choice between multiple daily injections and continuous subcutaneous insulin injections should be made only after both regimens are carefully explained to the patient. The choice of regimen is largely a matter of patient preference and lifestyle. It may be helpful to have patients receiving continuous therapy to talk with prospective patients and to have a patient use a borrowed pump for several days before buying one. We often ask patients to wear a pump (delivering saline only) for a week while continuing with their normal insulin regimen. This allows them to get a sense of what it would be like to be attached to the pump all the time. Patients choosing this regimen should have 24-hour access to expert advice.",
"   </p>",
"   <p>",
"    If multiple daily injections are chosen, it is often advisable to begin by maintaining the patient's preexisting insulin regimen while increasing the frequency of blood glucose monitoring and working to achieve nutritional consistency. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Blood glucose monitoring'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H23\">",
"     'Nutrition'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Multiple daily injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before the conclusion of the DCCT in 1993, the most commonly used insulin regimens (ie, \"conventional insulin therapy\") consisted of twice-daily injections of short-acting (regular) and intermediate-acting insulin. (",
"    <a class=\"graphic graphic_figure graphicRef59453 \" href=\"UTD.htm?9/2/9262\">",
"     figure 3",
"    </a>",
"    ). This regimen was not physiologic and is no longer recommended unless the patient cannot or will not comply with an intensive insulin regimen.",
"   </p>",
"   <p>",
"    Many different insulin regimens may be used to accomplish intensive insulin therapy. Some of the more common ones are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef69575 \" href=\"UTD.htm?28/9/28827\">",
"     table 2",
"    </a>",
"    ). The choice of basal and bolus insulins for a multiple daily injection (MDI) regimen depends upon patient preference, lifestyle, and cost concerns. Irrespective of the type of insulin chosen, these intensive insulin regimens should be monitored with frequent blood glucose determinations, at least four times per day. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Blood glucose monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8429972\">",
"    <span class=\"h3\">",
"     Basal insulin",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h4\">",
"     Insulin glargine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     Insulin glargine",
"    </a>",
"    is identical to human insulin except for a substitution of glycine for asparagine in position A21 and by the addition of two arginine molecules in the B-chain of the insulin molecule. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link&amp;anchor=H4#H4\">",
"     \"General principles of insulin therapy in diabetes mellitus\", section on 'Human versus analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These modifications result in a change in the pH such that after subcutaneous administration glargine precipitates in the tissue forming hexamers, which delays absorption and prolongs duration of action. The time-action profile for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    has virtually no peak (",
"    <a class=\"graphic graphic_figure graphicRef67242 \" href=\"UTD.htm?12/57/13214\">",
"     figure 4",
"    </a>",
"    ), which makes it a good basal insulin preparation for intensive insulin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The therapeutic advantage of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    over NPH is modest. In a pooled analysis of trials comparing glargine with NPH in adults with type 1 diabetes, the weighted mean difference in A1C was -0.11 percent (95% CI -0.21 to -0.02), favoring glargine [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/18\">",
"     18",
"    </a>",
"    ]. There was no difference in the number of hypoglycemic episodes. It is unclear whether the modest benefits of glargine compared with NPH merit the added expense and inconvenience of not being able to mix it with other insulins (sometimes requiring an additional injection, when compared with NPH regimens). In addition, there are few trials addressing long-term safety. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link&amp;anchor=H4#H4\">",
"     \"General principles of insulin therapy in diabetes mellitus\", section on 'Human versus analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with type 1 diabetes (but not type 2), glycemic control is similar if once-daily glargine is given before breakfast, before dinner, or at bedtime but there is less nocturnal hypoglycemia with breakfast administration. This was illustrated in a randomized trial of 378 patients with type 1 diabetes who received pre-meal doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17160?source=see_link\">",
"     insulin lispro",
"    </a>",
"    in addition to one of the three glargine regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/19\">",
"     19",
"    </a>",
"    ]. A1C was similar in the three groups, but nocturnal hypoglycemia occurred in 60 percent of patients taking glargine before breakfast, 72 percent before dinner, and 78 percent at bedtime.",
"   </p>",
"   <p>",
"    Although many patients can achieve stable basal serum insulin concentrations with a single daily injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    given in the morning or evening (regimens 3 and 4) (",
"    <a class=\"graphic graphic_table graphicRef69575 \" href=\"UTD.htm?28/9/28827\">",
"     table 2",
"    </a>",
"    ), this is not always the case. In our experience, some patients with type 1 diabetes achieve better glycemic control with glargine given twice per day (regimen 5) (",
"    <a class=\"graphic graphic_table graphicRef69575 \" href=\"UTD.htm?28/9/28827\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4232?source=see_link\">",
"     \"Cases illustrating problems with intensive insulin therapy for diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h4\">",
"     Insulin detemir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/49/25367?source=see_link\">",
"     Insulin detemir",
"    </a>",
"    is another available long-acting insulin analog. It is an insoluble molecule with a fatty acid side chain that allows albumin binding, which results in prolongation in action [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Insulin detemir is considerably less potent than human insulin and is formulated so that four detemir molecules have roughly the same potency as one molecule of human insulin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link&amp;anchor=H4#H4\">",
"     \"General principles of insulin therapy in diabetes mellitus\", section on 'Human versus analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Its duration of action appears to be substantially shorter than that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/22\">",
"     22",
"    </a>",
"    ], though still somewhat longer than NPH (",
"    <a class=\"graphic graphic_table graphicRef73676 \" href=\"UTD.htm?1/62/2028\">",
"     table 1",
"    </a>",
"    ). In one study, a detemir dose of 0.29",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    provided the same effect as 0.3",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    NPH, but with a longer duration of action (16.9 versus 12.7 hours, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/23\">",
"     23",
"    </a>",
"    ]. Like NPH, twice-daily injections appear to be necessary in patients with type 1 diabetes.",
"   </p>",
"   <p>",
"    Glycemic control appears to be similar in trials comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/49/25367?source=see_link\">",
"     insulin detemir",
"    </a>",
"    and NPH. In a pooled analysis of trials comparing detemir with NPH in patients with type 1 diabetes, there was no difference in A1C (weighted mean difference -0.06 percent, 95% CI -0.13 to 0.02) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/18\">",
"     18",
"    </a>",
"    ]. However, insulin detemir was associated with a slightly lower risk of severe hypoglycemia and nocturnal hypoglycemia. These modest advantages of insulin detemir may be offset by its higher cost and unknown long-term safety profile.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8429996\">",
"    <span class=\"h4\">",
"     Insulin degludec",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin degludec is a long-acting basal insulin available in some countries. It is almost identical to human insulin, except for deletion of the last amino acid from the B-chain and the addition of a glutamyl link from LysB29 to a hexadecanedioic fatty acid. This feature allows it to form soluble multihexamers at the injection site, from which monomers slowly separate and are absorbed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/24\">",
"     24",
"    </a>",
"    ]. This property confers a long duration of action (&gt;40 hours) and reduces variability in plasma concentration with once daily dosing.",
"   </p>",
"   <p>",
"    The duration of action, glycemic efficacy, and safety of insulin degludec appears to be similar to that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    , as illustrated by the findings of an open-label, non-inferiority trial comparing insulin glargine with insulin degludec (both administered once daily) in 629 adults with type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/25\">",
"     25",
"    </a>",
"    ]. All patients received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10920?source=see_link\">",
"     insulin aspart",
"    </a>",
"    pre-meals. After 52 weeks, the mean decrease in A1C between the two groups was similar (-0.4 percentage points), with an achieved mean A1C of approximately 7.3 percent. The mean weight gain (1.6 to 1.8 kg) and the rates of overall confirmed hypoglycemic episodes were also similar. There was a significant reduction in nocturnal hypoglycemia in patients randomly assigned to insulin degludec (4.4 versus 5.9 episodes per patient-year of exposure). However, the overall rate of nocturnal hypoglycemia was low, and the difference is of uncertain clinical significance. The long-term safety profile of insulin degludec is unknown. It is not available in the United States owing to concern regarding a potential increase in cardiovascular risk [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Rapid-acting insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;To produce an insulin preparation with a faster onset and shorter duration than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    , modifications have been made in the insulin molecule to prevent it from forming polymers and other complexes that slow absorption and delay action. The resulting rapid-acting insulins (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17160?source=see_link\">",
"     insulin lispro",
"    </a>",
"    , aspart, and glulisine) have an onset of action within 5 to 15 minutes, peak action at 45 to 75 minutes, and a duration of action of two to four hours. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link\">",
"     \"General principles of insulin therapy in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with type 1 diabetes, rapid-acting insulin has the following advantages when compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It decreases the postprandial rise in blood glucose concentration.",
"     </li>",
"     <li>",
"      It is more convenient because it can be injected 10 to 15 minutes prior to or up to immediately after meals, whereas",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"       regular insulin",
"      </a>",
"      should be given 30 to 45 minutes or more before meals to optimally match the glycemic excursions after a meal. In addition, the action of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17160?source=see_link\">",
"       insulin lispro",
"      </a>",
"      is not blunted by mixing with NPH insulin just before injection, as is the action of regular insulin [",
"      <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these advantages, the results from clinical trials have been somewhat disappointing [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/29\">",
"     29",
"    </a>",
"    ]. Meta-analyses of randomized trials (involving 5925 patients with type 1 diabetes) that compared rapid-acting insulin analogues with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    showed only a minor benefit of insulin analogs in terms of A1C values [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a subsequent pooled analysis of trials comparing lispro or aspart with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    in patients with type 1 diabetes, the insulin analogs provided a similar small improvement in A1C (weighted mean difference -0.09 to -0.13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/18\">",
"     18",
"    </a>",
"    ]. It is unclear if this small improvement will provide clinical benefit. There are no data examining the relative effects of insulin analogs on long-term diabetic complications. Nevertheless, the convenience for patients regarding timing of pre-meal administration represents a distinct advantage for patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link&amp;anchor=H4#H4\">",
"     \"General principles of insulin therapy in diabetes mellitus\", section on 'Human versus analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/18,32\">",
"     18,32",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/30,31\">",
"     30,31",
"    </a>",
"    ], meta-analyses comparing rapid-acting insulin analogs with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    , there was a lower risk of severe hypoglycemia with use of lispro. In a pooled analysis of trials comparing aspart and regular insulin, the risk of severe hypoglycemia was not significantly different [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rapid-acting insulins are particularly useful in addressing unexpectedly high blood glucose levels (eg, between meals or in the setting of stress) because they will lower glucose levels more rapidly and without the prolonged effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One disadvantage of rapid-acting insulins is their higher cost [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/27\">",
"     27",
"    </a>",
"    ]. The teratogenicity and long-term safety profile of short-acting insulins in pregnancy are unknown, although many diabetologists do prescribe rapid-acting insulins during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Choosing basal/bolus insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of basal and bolus insulin for a multiple daily injection regimen depends upon patient preference, lifestyle, and cost concerns. In short-term trials, there may be a modest glycemic benefit of analogs over conventional insulin. However, it is of uncertain clinical significance and long-term trials with diabetic complications as endpoints are lacking.",
"   </p>",
"   <p>",
"    As an example, in an 18-week trial in 595 adults with type 1 diabetes randomly assigned to",
"    <span class=\"nowrap\">",
"     NPH/regular",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     detemir/aspart,",
"    </span>",
"    there was a small but significant difference in A1C values (mean difference -0.22 percentage points) favoring the insulin analogs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/36\">",
"     36",
"    </a>",
"    ]. However, it should be noted that the patients in the analog group received a higher daily dose (by four units) of basal insulin. The risk of overall and nocturnal hypoglycemia was lower in the analog group.",
"   </p>",
"   <p>",
"    In a trial comparing insulins detemir and glargine in patients with type 1 diabetes (each in combination with premeal aspart), there was no difference in A1C values [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/37\">",
"     37",
"    </a>",
"    ]. Severe hypoglycemia occurred less often in patients taking detemir.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Designing an MDI insulin regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most newly diagnosed patients with type 1 diabetes can be started on a total daily dose of 0.2 to 0.4 units of insulin per kg per day, although most will ultimately require 0.6 to 0.7 units per kg per day. Adolescents, especially during puberty, often need more, but the dose can be adjusted upward every few days based upon symptoms and blood glucose measurements.",
"   </p>",
"   <p>",
"    In designing an MDI regimen, approximately one-half of the total dose should be given as a basal insulin, either as once or twice per day long-acting insulin (glargine or detemir) or as twice per day intermediate-acting insulin (NPH). The long-acting insulin can be given either at bedtime or in the morning; the NPH is usually given as approximately two-thirds of the dose in the morning and one-third at bedtime. The remainder of the total daily dose (TDD) is given as short or rapid-acting insulin, divided before meals. The pre-meal dosing is determined by the pre-meal glucose level, meal size and content, as well as activity and exercise pattern. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25641?source=see_link\">",
"     \"Nutritional considerations in type 1 diabetes mellitus\"",
"    </a>",
"    .) Regimens that use NPH in the morning may not require a pre-lunch dose of short or rapid-acting insulin.",
"   </p>",
"   <p>",
"    The shorter duration of action of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17160?source=see_link\">",
"     insulin lispro",
"    </a>",
"    , compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    , may result in hypoinsulinemia and hyperglycemia five to seven hours after injection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/38\">",
"     38",
"    </a>",
"    ]. The net effect is that an increase in the dose of intermediate- or long-acting insulin may be required when a patient is switched from regular (short-acting) insulin to a rapid-acting insulin for the pre-meal bolus dose. In a randomized clinical trial of 56 type 1 patients with diabetes using variable-dose lispro or regular insulin before meals along with twice-daily NPH insulin, A1C values were lower after 12 months (6.3 versus 6.7 percent) and hypoglycemia was less frequent (7.4 versus 11.5 episodes per month, defined as blood glucose concentrations less than 70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [3.8",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    in the insulin lispro group, but 30 percent more NPH insulin was required [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Continuous subcutaneous insulin infusion (insulin pump)",
"    </span>",
"    &nbsp;&mdash;&nbsp;With pump therapy, basal insulin is supplied in the form of a continuous infusion (comprising between 40 and 60 percent of the total daily dose) with pre-meal bolus doses given to minimize postprandial glucose excursions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4232?source=see_link&amp;anchor=H14#H14\">",
"     \"Cases illustrating problems with intensive insulin therapy for diabetes mellitus\", section on 'Late morning hyperglycemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Choice of insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only short-acting insulin (regular) or rapid-acting insulins are used with continuous therapy. In a double-blind crossover trial,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17160?source=see_link\">",
"     insulin lispro",
"    </a>",
"    , compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    , resulted in greater reduction in postprandial blood glucose concentrations (by 25",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.4",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    lower A1C (by 0.3 percent), fewer episodes of hypoglycemia, and less weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/40\">",
"     40",
"    </a>",
"    ]. In a 16-week trial comparing insulin apart, insulin lispro, and regular insulin, there were no differences in A1C or rates of hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/41\">",
"     41",
"    </a>",
"    ]. Rapid-acting insulin analogs (lispro, aspart, and glulisine) are typically preferred over regular insulin for continuous insulin therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Getting started",
"    </span>",
"    &nbsp;&mdash;&nbsp;When converting a patient from a multiple daily insulin regimen to continuous insulin therapy, the pre-pump level of chronic glycemia will help determine the pump basal rate and pre-prandial scales chosen. As an example, for a patient who has been well controlled on his previous multiple injection regimen (eg, A1C &lt;7.0 percent), the initial total daily dose of insulin administered by pump may be 10 to 20 percent less than the total daily dose of the previous regimen. Conversely, patients with inadequate glycemic control may be started with the same total daily dose as they had been using with their injection regimens.",
"   </p>",
"   <p>",
"    In general, approximately one-half of the total daily dose is administered as basal rate. For most patients, basal rates are in the range of 0.01 to 0.015 units per kg per hour (ie, for a 60 kg woman approximately 0.6 to 0.9 units per hour). The basal rates are adjusted empirically based on glucose monitoring results.",
"   </p>",
"   <p>",
"    Certain time periods during the day may require higher, while other periods may require lower, infusion rates depending on individual factors including lifestyle and the \"dawn phenomenon\" which often occurs between 2 AM and 8 AM. Most pumps allow for pre-programmed changes in basal rate to accommodate these requirements. The \"dawn phenomenon\" is thought to result from increased secretion of hormones, particularly growth hormone, that tend to antagonize the actions of insulin and so raise blood glucose concentrations. The overnight rate can be adjusted to maintain the prebreakfast blood glucose in the target range. When changing the subcutaneous basal insulin infusion rate, a delay in the actual increase or decrease in plasma insulin levels must be taken into account, based on the kinetics of absorption and time to reach a new steady state [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/42\">",
"     42",
"    </a>",
"    ]. Therefore, basal rates of rapid-acting insulin should be changed about two to four hours before the change in plasma level is required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=see_link\">",
"     \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The premeal bolus dose should be based upon the carbohydrate content of the intended meal and the blood glucose level immediately before the meal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25641?source=see_link&amp;anchor=H9#H9\">",
"     \"Nutritional considerations in type 1 diabetes mellitus\", section on 'Advanced carbohydrate counting'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Advantages",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19362664\">",
"    <span class=\"h4\">",
"     Insulin pump",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous subcutaneous insulin infusion (CSII) therapy has been used successfully in both research studies like the DCCT and in large clinical practices [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Continuous subcutaneous insulin infusion is increasingly used in the pediatric population. A randomized trial in 32 children and adolescents (aged 8 to 21 years) with type 1 diabetes showed that lower A1C and premeal glucose levels were more achievable with continuous subcutaneous insulin infusion than with an insulin regimen using once daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    and premeal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10920?source=see_link\">",
"     insulin aspart",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/45\">",
"     45",
"    </a>",
"    ]. In some children with type 1 diabetes who have frequent and severe nocturnal hypoglycemia, use of an insulin pump at nighttime only (with pre-breakfast NPH insulin and three pre-meal doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17160?source=see_link\">",
"     insulin lispro",
"    </a>",
"    during the day) can improve overall glycemic control and reduce hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40090?source=see_link&amp;anchor=H21#H21\">",
"     \"Management of type 1 diabetes mellitus in children and adolescents\", section on 'Insulin pump'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another potential advantage of insulin pump therapy is that it allows more flexibility in the timing of meals. If someone has taken NPH insulin before breakfast, its action is likely to be maximal around lunchtime or early afternoon. Thus, delaying lunch can lead to hypoglycemia. With continuous therapy, the steady basal infusion should maintain normoglycemia but not induce hypoglycemia. This relative advantage may also pertain to multiple injection regimens that use analogues instead of NPH.",
"   </p>",
"   <p>",
"    In addition, insulin absorption with pump therapy is less variable from day to day [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/47\">",
"     47",
"    </a>",
"    ], and therefore blood glucose profiles may be more predictable. Both the small subcutaneous depot and the constancy of the injection site and depth for the two to three days with each catheter contribute to the relative consistency of absorption. Furthermore, dosing of small doses of insulin can be achieved with CSII not possible with syringes or pens. Doses as low as 0.05 units can be accurately delivered with CSII. While these extremely small doses of insulin may not be clinically important for most, non-pump insulin delivery can only provide insulin at 1.0 unit increments which for some patients is too much, especially when considering basal insulin dosing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19362671\">",
"    <span class=\"h4\">",
"     Sensor-augmented insulin pump",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous subcutaneous insulin has also been used in conjunction with a continuous glucose monitoring (CGM) device to give the patient more information about their blood glucose levels and allow them to make better informed decisions about insulin dosing. This approach is known as sensor-augmented insulin pump therapy. A randomized trial compared sensor-augmented insulin pump therapy with MDI in 329 adults [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/48\">",
"     48",
"    </a>",
"    ]. After one year, the reduction in mean A1C was significantly greater in the pump therapy group (between group difference -0.6 percentage points). The improvement in glycemic controls was not associated with an increase in the rate of severe hypoglycemia. These results suggest that CSII in conjunction with continuous glucose monitoring may effectively improve glycemia while limiting the rise in hypoglycemia that often accompanies improved glycemic control. Of note, the design of the study (augmented pump therapy versus MDI without CGM) could not distinguish between the effects of pump therapy and CGM. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=see_link&amp;anchor=H13#H13\">",
"     \"Blood glucose self-monitoring in management of adults with diabetes mellitus\", section on 'Continuous glucose monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19362678\">",
"    <span class=\"h4\">",
"     Automated closed-loop insulin pump",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies are currently evaluating the efficacy of a fully automated closed loop system of insulin delivery based upon continuous glucose sensing.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized cross-over trial comparing an overnight closed loop insulin delivery system with conventional insulin pump therapy in 24 adults with type 1 diabetes, the closed loop delivery system significantly increased the time plasma glucose levels were in target by a median of 22 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/49\">",
"       49",
"      </a>",
"      ]. The closed loop system also significantly reduced nocturnal hypoglycemia by 3 percent. During the trial, study personnel transmitted data manually from the continuous glucose monitor to the computer running the closed loop system and from the computer to the insulin pump (so the system was not fully automated).",
"     </li>",
"     <li>",
"      In a trial comparing a fully automated closed-loop system versus a sensor-augmented insulin pump in children 10 to 18 years of age, there was better overnight glycemic control with less nocturnal hypoglycemia with the automated closed-loop system (7 versus 22 episodes of nighttime glucose levels &lt;63",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [3.5",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Small short-term studies reported near normal glucose levels with the use of a bi-hormonal (insulin and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"       glucagon",
"      </a>",
"      ) closed-loop system and no hypoglycemic events [",
"      <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/51,52\">",
"       51,52",
"      </a>",
"      ]. In a small randomized trial, a bi-hormonal closed-loop system significantly improved short-term glucose control and reduced the risk of hypoglycemia compared with standard insulin-pump therapy guided by less frequent self-monitoring of blood glucose [",
"      <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these preliminary results are promising, additional trials using a fully automated sensor-pump communication system are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Disadvantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are, however, disadvantages to continuous therapy. The costs of the pump and supplies are higher than those of ordinary syringes and needles. Complications of pump therapy may include superficial infection or system failure. System failure is usually due to blockage or leakage in the syringe or the infusion set or connectors, causing an interruption of infusion flow [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Since the subcutaneous depot is so small, any interruption in continuous flow leads very quickly to hypoinsulinemia, hyperglycemia, and possibly diabetic ketoacidosis. Ketoacidosis occurs more rapidly (four versus six hours) in patients with pump malfunction who are using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17160?source=see_link\">",
"     insulin lispro",
"    </a>",
"    rather than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/56\">",
"     56",
"    </a>",
"    ]. However, these issues now occur less commonly with more modern pumps and supplies.",
"   </p>",
"   <p>",
"    Finally, many patients prefer not to have to wear a device and be \"tethered\" to the pump at all times. Some patients who use pumps complain that the treatment is awkward, embarrassing, or unpleasant, particularly when sleeping or having sexual intercourse. Pump-treated patients can take off the pump for brief periods. Doing so for one hour or less does not usually lead to loss of blood glucose control. For longer periods (such as overnight), a subcutaneous dose of intermediate-acting insulin should be given in a dose 1.5 to 2 times the calculated basal infusion rate for that period [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/57\">",
"     57",
"    </a>",
"    ]. Some patients also like to stop pump therapy and use multiple daily injection therapy for more prolonged periods, such as summer vacations, to allow water activities. These transitions are usually easy to make if planned ahead of time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Inhaled insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;An inhaled form of rapid-acting insulin was available for a short time but was discontinued in 2007. Another inhaled insulin preparation is in clinical trials but is not currently available. Studies have shown that inhaled insulin causes a very rapid rise in serum insulin concentration (similar to that after subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17160?source=see_link\">",
"     insulin lispro",
"    </a>",
"    and aspart, and faster than that after subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link&amp;anchor=H10#H10\">",
"     \"General principles of insulin therapy in diabetes mellitus\", section on 'Inhaled insulin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are several trials in patients with type 1 diabetes in which inhaled insulin was found to have similar efficacy as subcutaneous regular or lispro insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. However, in these studies, neither the inhaled insulin nor the control arms achieved optimal glycemic efficacy that has been achieved with injection regimens in previous trials with insulin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     OTHER MANAGEMENT ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of other issues that must be addressed in patients receiving multiple daily insulin injections or continuous subcutaneous insulin infusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Consistency",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important that the patient be disciplined and consistent in the content and timing of meals, the site of insulin injections, and the timing and frequency of exercise. This makes it much easier to interpret blood glucose patterns and make appropriate alterations to the regimen. Compared with previous non-physiologic fixed dose regimens, current intensive regimens provide somewhat more flexibility in timing of meals, meal size, and composition, since timing and size of doses can be varied. However, it is difficult to achieve A1C goals without some degree of consistency in eating patterns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Blood glucose monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of relatively inexpensive, simple, and accurate meters and strips to measure the blood glucose concentration has revolutionized diabetes management. Ideally, testing at home should to be done four to seven times daily (before breakfast, mid-morning, before lunch, mid-afternoon, before the evening meal, before bedtime, and occasionally at 3 AM). Additionally, it is useful to test blood glucose levels at intervals after certain meals and before, during, and after exercise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=see_link\">",
"     \"Blood glucose self-monitoring in management of adults with diabetes mellitus\"",
"    </a>",
"    .) Chronic glucose control should be monitored with periodic A1C (hemoglobin A1c or HbA1c) levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=see_link\">",
"     \"Blood glucose self-monitoring in management of adults with diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11993?source=see_link\">",
"     \"Estimation of blood glucose control in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of all the behavioral aspects of diabetes management, none is more important than nutrition. However, nutritional control is usually not done well by patients and is largely ignored by clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most important component of the dietary approach is for the patient to learn to estimate how much carbohydrate they are about to consume at any meal or snack. One approach is to ask the patient to maintain a consistent carbohydrate profile in which the same amount of carbohydrate is consumed each day at any particular meal (",
"    <a class=\"graphic graphic_figure graphicRef76488 \" href=\"UTD.htm?31/4/31821\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25641?source=see_link\">",
"     \"Nutritional considerations in type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A second, more modern approach allows for flexibility in carbohydrate consumption, matching insulin delivery to insulin requirements based upon the patient understanding the anticipated glucose excursion with meals and selecting a dose of short or rapid-acting insulin that will control post-prandial blood glucose excursions. Use of carbohydrate-to-insulin ratios can free patients from having to take a fixed amount of carbohydrate at particular meals. If they plan to eat less carbohydrate at a meal they simply decrease the dose of short-acting insulin they take before the meal.",
"   </p>",
"   <p>",
"    Patients vary considerably in how much insulin they need to cover a set amount of carbohydrate. Some patients need a different \"carbohydrate-to-insulin ratio\" at different meals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25641?source=see_link\">",
"     \"Nutritional considerations in type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incorporating regular exercise into an intensive therapy program is helpful to avoid weight gain frequently induced by increased insulin administration [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/63\">",
"     63",
"    </a>",
"    ]. There are two aspects that are important to consider. First, the effect of exercise on blood glucose varies with the time of day, and whether the person is hypoinsulinemic or hyperinsulinemic at that time. Second, late hypoglycemia can occur several hours after vigorous exercise due to repletion of muscle glycogen stores. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20265?source=see_link\">",
"     \"Effects of exercise in diabetes mellitus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased risk of hypoglycemia is the major complication of attempts at strict glycemic control [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/64\">",
"     64",
"    </a>",
"    ]. The final results from the DCCT, as an example, showed an inverse correlation between the A1C value and frequency of hypoglycemic episodes (",
"    <a class=\"graphic graphic_figure graphicRef59452 \" href=\"UTD.htm?5/41/5789\">",
"     figure 6",
"    </a>",
"    ). The risk of severe hypoglycemia that required the assistance of another person was higher in males, adolescents, and in those with a history of severe hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is wide interpatient variability in the rate of hypoglycemia for a given A1C value. Some patients are able to maintain an A1C value below 6.5 percent for years without hypoglycemia, while others will have frequent and disabling hypoglycemic events with an A1C less than 8.0 percent. Thus, each patient must find his or her own level of tolerance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27641?source=see_link\">",
"     \"Management of hypoglycemia during treatment of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nocturnal hypoglycemia has been shown to be common in patients with type 1 diabetes treated with twice daily insulin injections (usually a mixed injection of short-acting and NPH insulin in the morning and at dinnertime). In a randomized, controlled trial of 22 patients with type 1 diabetes, splitting the evening insulin regimen into short-acting insulin at dinner and NPH insulin at bedtime reduced the risk of nocturnal hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/65\">",
"     65",
"    </a>",
"    ]. Switching to a long-acting insulin analog with a flatter profile of insulin delivery (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    ) may also reduce the risk of nocturnal hypoglycemia. In contrast, when compared with multiple daily injections, the use of continuous subcutaneous insulin infusion has not been found to consistently reduce hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The fear of hypoglycemia is often not expressed openly by patients, but can be a substantial barrier to achieving strict glycemic control with intensive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/66\">",
"     66",
"    </a>",
"    ]. It is therefore important to address this issue directly with any patient contemplating intensive therapy. Educational strategies need to focus on how to help the patient live safely with the increased risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27641?source=see_link\">",
"     \"Management of hypoglycemia during treatment of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Weight gain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight gain is a common problem with intensive insulin regimens. Patients randomly assigned to intensive insulin therapy in the DCCT gained significantly more weight than those who received conventional therapy (5.1 versus 2.4 kg) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/63\">",
"     63",
"    </a>",
"    ]. Higher baseline A1C values and greater decrements in A1C during intensive therapy were both associated with greater weight gain.",
"   </p>",
"   <p>",
"    The potential importance of these findings is illustrated in a subsequent report from the DCCT [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/67\">",
"     67",
"    </a>",
"    ]. In this analysis, patients were divided into quartiles based upon weight gain, from no weight gain (first quartile) to maximal weight gain (fourth quartile). The mean body mass index (BMI) in the fourth quartile was 31",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    placing these patients in the obesity range. The following results were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intensive insulin therapy resulted in similar glycemic control at follow-up (mean 6.1 years) in all the weight gain quartiles.",
"     </li>",
"     <li>",
"      Patients in the first quartile (no weight gain) had decreases in serum triglyceride, total cholesterol, and low-density lipoprotein (LDL) cholesterol concentrations compared with baseline, reflecting the benefits of improved glycemic control on serum lipid concentrations in the absence of weight gain.",
"     </li>",
"     <li>",
"      Patients in the fourth quartile had a significant elevation in serum concentrations of these lipids and in blood pressure compared with baseline. They also had a higher waist-to-hip ratios (abdominal obesity) than patients in other quartiles.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The constellation of lipid abnormalities, abdominal obesity, and hypertension is similar to that in the central obesity-insulin resistance syndrome that is characteristic of many patients with type 2 diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .) Such patients are predisposed to develop coronary atherosclerosis, although it is unproven whether control of weight gain could be important in decreasing the risk of macrovascular complications in patients receiving intensive insulin therapy. Excessive weight gain might detract from the demonstrated benefit of intensive therapy on macrovascular complications demonstrated by the",
"    <span class=\"nowrap\">",
"     DCCT/EDIC",
"    </span>",
"    study [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Noncompliance may also be a problem in patients concerned about weight gain. As an example, in two studies of women with type 1 diabetes, 31 percent intentionally omitted insulin injections occasionally [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/68\">",
"     68",
"    </a>",
"    ] and 8.8 percent did so on a regular basis in order to avoid weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Special situations",
"    </span>",
"    &nbsp;&mdash;&nbsp;An occasional lapse of dietary control during a special occasion (such as eating at a restaurant or traveling) is to be expected. However, patients should be educated so that they can adjust their insulin regimens without developing a marked fluctuation in the plasma glucose concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28178?source=see_link\">",
"     \"Illustrative cases of intensive insulin therapy in special situations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     APPROACH TO THE PATIENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;A good general approach to insulin management in type 1 diabetes is to begin by exploring the patient's understanding of diabetes, blood glucose regulation, the relationship between long-term glycemic levels and diabetic complications, and the potential for increased hypoglycemia and weight gain with an intensive regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Insulin technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's technique for drawing up and injecting insulin should also be reviewed. The abdomen is the preferred site for pre-meal injections of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    , because absorption is quicker from this site [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/70\">",
"     70",
"    </a>",
"    ]. In comparison, the thigh or buttock is a good site for the evening intermediate-acting insulin (NPH) dose; the slower rate of absorption enhances the likelihood that the insulin will last through the night. The site of injection is less important for rapid-acting or long-acting insulin analogs, and therefore they may be administered in the abdomen, thighs, buttock, or upper arms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link\">",
"     \"General principles of insulin therapy in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Glucose patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before instituting any changes in therapy, it is useful to review the patient's blood glucose monitoring technique. The patient should then keep detailed food records and measure blood glucose four to seven times daily for several weeks. The results obtained should be reviewed so that the patient can learn how to interpret the findings and how to make appropriate adjustments in dietary intake and insulin dose.",
"   </p>",
"   <p>",
"    A number of different patterns and problems can be identified during this initial period. If the blood glucose records show no consistent pattern, the problem is usually an erratic lifestyle and eating pattern. This can be approached by either asking the patient to maintain a more consistent carbohydrate profile from day to day (eating the same amount of carbohydrate at the same times of each day) or by helping the patient to estimate how much carbohydrate they are about to eat and adjust their pre-meal dose of short- or rapid-acting insulin accordingly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4232?source=see_link\">",
"     \"Cases illustrating problems with intensive insulin therapy for diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If postprandial rises in blood glucose are too high, consider either modifying the content of the diet (including more high-fiber, slowly absorbed carbohydrate), increasing the time between when the insulin is given and the meal is started, or adjusting the pre-prandial dose. Alternatively, if it is not already being used, try replacing the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    with a rapid-acting insulin, which is absorbed and therefore acts more rapidly than regular insulin, resulting in lower postprandial blood glucose values [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link\">",
"     \"General principles of insulin therapy in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Insulin algorithm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over a period of a few weeks, lifestyle adjustments to diet and exercise can be made along with modifications in the insulin regimen until a new prescription is established with which the patient is comfortable. At this time, an insulin algorithm can be introduced to allow continual adjustments before each meal to try to keep blood glucoses within safe and mutually agreed upon targets. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4232?source=see_link&amp;anchor=H8#H8\">",
"     \"Cases illustrating problems with intensive insulin therapy for diabetes mellitus\", section on 'Insulin algorithm'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the increased risk of hypoglycemia as the blood glucose concentration is lowered to near normal [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/64\">",
"     64",
"    </a>",
"    ], it is important to ensure that the patient's family or partner is well equipped to deal with symptomatic hypoglycemia and that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    is available for emergency use. Attention should also be paid to caloric content and exercise to avoid the weight gain which commonly accompanies the institution of intensive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/20/24906/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of clinic visits and adjustments to the regimen vary with the preference of the patient and health care team. At a minimum, patients with type 1 diabetes should be seen every three months. For a well-educated person, many day-to-day problems can be solved over the telephone or via e-mail (especially if blood glucoses have been faxed in or e-mailed prior to the conversation). There should be agreement on a target A1C level, which should be checked at least every three months.",
"   </p>",
"   <p>",
"    Maintaining improved glycemic control over the long-term requires a major effort to prevent complacency and to avoid burn-out. It is often helpful to focus on one particular aspect (such as exercise, diet, or carbohydrate-to-insulin ratios) for a few weeks, and then switch to another issue. Giving the patient written feedback on how they are doing (graphing out their changes in weight, A1C, etc) may also be useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=see_link\">",
"       \"Patient information: Type 1 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/58/28579?source=see_link\">",
"       \"Patient information: Using insulin (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/47/6899?source=see_link\">",
"       \"Patient information: Should I switch to an insulin pump? (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/31/35317?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"       \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend intensive insulin therapy with the goal of achieving glycemic control as close to the non-diabetic range as safely possible for the majority of patients with type 1 diabetes (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Intensive therapy for type 1 diabetes reduces retinopathy, nephropathy, neuropathy, and cardiovascular disease, and is now considered standard of care. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intensive therapy involves administration of a basal level of insulin (delivered by daily or twice daily injections of a long-acting insulin preparation, or continuous subcutaneous delivery of a short or rapid insulin preparation via a pump) and premeal boluses of a short or rapid-acting insulin. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pretreatment considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intensive insulin regimens require commitment by the patient, support by an experienced clinical team, and acceptance of side effects of increased hypoglycemic episodes and increased weight gain. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Choice of insulin regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several regimens are available to accomplish intensive insulin therapy (",
"      <a class=\"graphic graphic_table graphicRef69575 \" href=\"UTD.htm?28/9/28827\">",
"       table 2",
"      </a>",
"      ). Both continuous infusion and multiple daily injection regimens should be discussed in detail as options for patients. The choice of regimen depends upon patient preference and lifestyle. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Choice of insulin regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of basal and bolus insulin for a multiple daily injection regimen depends upon patient preference, lifestyle, and cost concerns. Although in short-term trials there was a modest glycemic benefit (modest reduction in A1C",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      rate of severe hypoglycemia) of long-acting (glargine, detemir) and rapid-acting (lispro, aspart, glulisine) insulin analogs over conventional insulin (NPH and regular), it is of uncertain clinical significance and long-term trials with diabetic complications as endpoints are lacking. In addition, the modest benefit is offset by higher cost and unknown long-term safety profile. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Choosing basal/bolus insulin'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link&amp;anchor=H4#H4\">",
"       \"General principles of insulin therapy in diabetes mellitus\", section on 'Human versus analogs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It is preferable to give the intermediate-acting insulin (NPH) as a separate injection into a site (leg or buttock) from which absorption is slow and the pre-meal bolus doses of short-acting (regular) insulin into a site (abdomen) from which insulin is absorbed more rapidly. The site of injection is less important for the rapid-acting (lispro, aspart, glulisine) or long-acting (glargine, detemir) insulin analogs, and therefore they may be administered in the abdomen, thighs, buttock, or upper arms. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Multiple daily injections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Continuous subcutaneous insulin infusion (insulin pump) uses only short or rapid-acting insulins and may provide a slight improvement in glycemic control, on average, compared with multiple daily injection regimens. Rapid-acting insulins are preferable to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"       regular insulin",
"      </a>",
"      . Ketoacidosis may occur if the pump malfunctions, and it is costly and cumbersome for some patients. Patients choosing this regimen should have 24-hour access to expert advice. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Continuous subcutaneous insulin infusion (insulin pump)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Blood glucose monitoring, using a glucose meter to read the test strips, should be done four to seven times daily (ideally before meals, mid-morning, mid-afternoon, before bedtime, and occasionally at 3 AM). A1C should be tested regularly to determine chronic glucose control. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Blood glucose monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Weight gain, hypoglycemia management, nutrition with carbohydrate counting, and exercise should be reviewed with the patient. Patients should be seen every three months minimally, with as-needed telephone or e-mail consultations for insulin regimen adjustments. Written feedback can help keep patients motivated to comply with their regimen. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Approach to the patient'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/1\">",
"      The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/2\">",
"      Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/3\">",
"      Egger M, Davey Smith G, Stettler C, Diem P. Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus: a meta-analysis. Diabet Med 1997; 14:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/4\">",
"      Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. JAMA 1996; 276:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/5\">",
"      Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 1998; 128:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/6\">",
"      Jeitler K, Horvath K, Berghold A, et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia 2008; 51:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/7\">",
"      Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002; 324:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/8\">",
"      Fatourechi MM, Kudva YC, Murad MH, et al. Clinical review: Hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J Clin Endocrinol Metab 2009; 94:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/9\">",
"      Misso ML, Egberts KJ, Page M, et al. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev 2010; :CD005103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/10\">",
"      Yeh HC, Brown TT, Maruthur N, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med 2012; 157:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/11\">",
"      Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008; 25:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/12\">",
"      Pickup JC. Insulin-pump therapy for type 1 diabetes mellitus. N Engl J Med 2012; 366:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/13\">",
"      Tsui E, Barnie A, Ross S, et al. Intensive insulin therapy with insulin lispro: a randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection. Diabetes Care 2001; 24:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/14\">",
"      Bolli GB, Kerr D, Thomas R, et al. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study. Diabetes Care 2009; 32:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/15\">",
"      Heinemann L, Linkeschova R, Rave K, et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/16\">",
"      Rosenstock J, Park G, Zimmerman J, U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diabetes Care 2000; 23:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/17\">",
"      Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49:2142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/18\">",
"      Singh SR, Ahmad F, Lal A, et al. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 2009; 180:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/19\">",
"      Hamann A, Matthaei S, Rosak C, et al. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care 2003; 26:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/20\">",
"      Havelund S, Plum A, Ribel U, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 2004; 21:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/21\">",
"      Insulin detemir (Levemir), a new long-acting insulin. Med Lettr Drugs Ther 2006; 48:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/22\">",
"      Porcellati F, Rossetti P, Busciantella NR, et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care 2007; 30:2447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/23\">",
"      Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005; 28:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/24\">",
"      Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012; 29:2104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/25\">",
"      Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/26\">",
"      Torjesen I. FDA raises concerns about ultra-long acting insulins given green light in Europe and Japan. BMJ 2012; 345:e7323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/27\">",
"      Hirsch IB. Insulin analogues. N Engl J Med 2005; 352:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/28\">",
"      Joseph SE, Korzon-Burakowska A, Woodworth JR, et al. The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. Diabetes Care 1998; 21:2098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/29\">",
"      Barnett AH, Owens DR. Insulin analogues. Lancet 1997; 349:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/30\">",
"      Plank J, Siebenhofer A, Berghold A, et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005; 165:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/31\">",
"      Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2006; :CD003287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/32\">",
"      Brunelle BL, Llewelyn J, Anderson JH Jr, et al. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 1998; 21:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/33\">",
"      Holleman F, van den Brand JJ, Hoven RA, et al. Comparison of LysB28, ProB29-human insulin analog and regular human insulin in the correction of incidental hyperglycemia. Diabetes Care 1996; 19:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/34\">",
"      Raskin P, Guthrie RA, Leiter L, et al. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000; 23:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/35\">",
"      Rave K, Klein O, Frick AD, Becker RH. Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes. Diabetes Care 2006; 29:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/36\">",
"      Hermansen K, Fontaine P, Kukolja KK, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004; 47:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/37\">",
"      Pieber TR, Treichel HC, Hompesch B, et al. Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. Diabet Med 2007; 24:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/38\">",
"      Torlone E, Pampanelli S, Lalli C, et al. Effects of the short-acting insulin analog [Lys(B28),Pro(B29)] on postprandial blood glucose control in IDDM. Diabetes Care 1996; 19:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/39\">",
"      Lalli C, Ciofetta M, Del Sindaco P, et al. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 1999; 22:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/40\">",
"      Zinman B, Tildesley H, Chiasson JL, et al. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 1997; 46:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/41\">",
"      Bode B, Weinstein R, Bell D, et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care 2002; 25:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/42\">",
"      Hildebrandt P, Birch K, Jensen BM, K&uuml;hl C. Subcutaneous insulin infusion: change in basal infusion rate has no immediate effect on insulin absorption rate. Diabetes Care 1986; 9:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/43\">",
"      Mecklenburg RS, Benson EA, Benson JW Jr, et al. Long-term metabolic control with insulin pump therapy. Report of experience with 127 patients. N Engl J Med 1985; 313:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/44\">",
"      Mecklenburg RS, Benson JW Jr, Becker NM, et al. Clinical use of the insulin infusion pump in 100 patients with type I diabetes. N Engl J Med 1982; 307:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/45\">",
"      Doyle EA, Weinzimer SA, Steffen AT, et al. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004; 27:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/46\">",
"      Kaufman FR, Halvorson M, Kim C, Pitukcheewanont P. Use of insulin pump therapy at nighttime only for children 7-10 years of age with type 1 diabetes. Diabetes Care 2000; 23:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/47\">",
"      Sindelka G, Heinemann L, Berger M, et al. Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects. Diabetologia 1994; 37:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/48\">",
"      Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010; 363:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/49\">",
"      Hovorka R, Kumareswaran K, Harris J, et al. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. BMJ 2011; 342:d1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/50\">",
"      Phillip M, Battelino T, Atlas E, et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med 2013; 368:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/51\">",
"      El-Khatib FH, Russell SJ, Nathan DM, et al. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med 2010; 2:27ra27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/52\">",
"      Russell SJ, El-Khatib FH, Nathan DM, et al. Blood glucose control in type 1 diabetes with a bihormonal bionic endocrine pancreas. Diabetes Care 2012; 35:2148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/53\">",
"      Haidar A, Legault L, Dallaire M, et al. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial. CMAJ 2013; 185:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/54\">",
"      Mecklenburg RS, Benson EA, Benson JW Jr, et al. Acute complications associated with insulin infusion pump therapy. Report of experience with 161 patients. JAMA 1984; 252:3265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/55\">",
"      Mecklenburg RS, Guinn TS, Sannar CA, Blumenstein BA. Malfunction of continuous subcutaneous insulin infusion systems: a one-year prospective study of 127 patients. Diabetes Care 1986; 9:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/56\">",
"      Pein, M, Hinselmann, C, Pf&uuml;tzner, A, Dreyer, M. Catheter disconnection in type 1 diabetic patients treated with CSII: comparison of insulin lispro and human regular insulin. Diabetologia 1996; 39(Suppl 1):A223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/57\">",
"      Helve E, Pelkonen R, Koivisto VA. Overnight interruption of wearing insulin pump: substitution dose and injection site of insulin. Diabetes Care 1986; 9:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/58\">",
"      Garg S, Rosenstock J, Silverman BL, et al. Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes. Diabetologia 2006; 49:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/59\">",
"      Ceglia L, Lau J, Pittas AG. Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann Intern Med 2006; 145:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/60\">",
"      McCulloch DK, Young RJ, Steel JM, et al. Effect of dietary compliance on metabolic control in insulin-dependent diabetics. Hum Nutr Appl Nutr 1983; 37:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/61\">",
"      McCulloch DK, Mitchell RD, Ambler J, Tattersall RB. Influence of imaginative teaching of diet on compliance and metabolic control in insulin dependent diabetes. Br Med J (Clin Res Ed) 1983; 287:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/62\">",
"      McCulloch DK, Mitchell RD, Ambler J, Tattersall RB. A prospective comparison of 'conventional' and high carbohydrate/high fibre/low fat diets in adults with established type 1 (insulin-dependent) diabetes. Diabetologia 1985; 28:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/63\">",
"      Weight gain associated with intensive therapy in the diabetes control and complications trial. The DCCT Research Group. Diabetes Care 1988; 11:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/64\">",
"      Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997; 46:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/65\">",
"      Fanelli CG, Pampanelli S, Porcellati F, et al. Administration of neutral protamine Hagedorn insulin at bedtime versus with dinner in type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control. A randomized, controlled trial. Ann Intern Med 2002; 136:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/66\">",
"      Irvine AA, Cox D, Gonder-Frederick L. Fear of hypoglycemia: relationship to physical and psychological symptoms in patients with insulin-dependent diabetes mellitus. Health Psychol 1992; 11:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/67\">",
"      Purnell JQ, Hokanson JE, Marcovina SM, et al. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA 1998; 280:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/68\">",
"      Polonsky WH, Anderson BJ, Lohrer PA, et al. Insulin omission in women with IDDM. Diabetes Care 1994; 17:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/69\">",
"      Biggs MM, Basco MR, Patterson G, Raskin P. Insulin withholding for weight control in women with diabetes. Diabetes Care 1994; 17:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/20/24906/abstract/70\">",
"      Koivisto VA, Felig P. Alterations in insulin absorption and in blood glucose control associated with varying insulin injection sites in diabetic patients. Ann Intern Med 1980; 92:59.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1796 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-E943584887-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_20_24906=[""].join("\n");
var outline_f24_20_24906=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRETREATMENT CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Drawbacks to intensive insulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      When to start intensive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CHOICE OF INSULIN REGIMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Multiple daily injections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8429972\">",
"      - Basal insulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Insulin glargine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Insulin detemir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8429996\">",
"      Insulin degludec",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Rapid-acting insulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Choosing basal/bolus insulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Designing an MDI insulin regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Continuous subcutaneous insulin infusion (insulin pump)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Choice of insulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Getting started",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Advantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19362664\">",
"      Insulin pump",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19362671\">",
"      Sensor-augmented insulin pump",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19362678\">",
"      Automated closed-loop insulin pump",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Disadvantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Inhaled insulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      OTHER MANAGEMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Consistency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Blood glucose monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Weight gain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Special situations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      APPROACH TO THE PATIENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Patient education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Insulin technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Glucose patterns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Insulin algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1796\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1796|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/32/29197\" title=\"figure 1\">",
"      Strict glycemic control slows progression of retinopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/21/18781\" title=\"figure 2\">",
"      Nephropathy and control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/2/9262\" title=\"figure 3\">",
"      Time course of insulin action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/57/13214\" title=\"figure 4\">",
"      Insulin glargine versus NPH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/4/31821\" title=\"figure 5\">",
"      Carbohydrate profiles in IDDM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/41/5789\" title=\"figure 6\">",
"      Hypoglycemia and HbA1c",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1796|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/62/2028\" title=\"table 1\">",
"      Insulin pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/9/28827\" title=\"table 2\">",
"      Multiple daily insulin inject",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=related_link\">",
"      Blood glucose self-monitoring in management of adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4232?source=related_link\">",
"      Cases illustrating problems with intensive insulin therapy for diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20265?source=related_link\">",
"      Effects of exercise in diabetes mellitus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11993?source=related_link\">",
"      Estimation of blood glucose control in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=related_link\">",
"      General principles of insulin therapy in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=related_link\">",
"      Glycemic control and intensive insulin therapy in critical illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28178?source=related_link\">",
"      Illustrative cases of intensive insulin therapy in special situations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=related_link\">",
"      Insulin therapy in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/48/5889?source=related_link\">",
"      Interactive diabetes case 1: Inpatient management in type 1 diabetes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/20/9538?source=related_link\">",
"      Interactive diabetes case 3: Hypoglycemia in a patient with type 1 diabetes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27641?source=related_link\">",
"      Management of hypoglycemia during treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40090?source=related_link\">",
"      Management of type 1 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25641?source=related_link\">",
"      Nutritional considerations in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/31/35317?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=related_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/47/6899?source=related_link\">",
"      Patient information: Should I switch to an insulin pump? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/58/28579?source=related_link\">",
"      Patient information: Using insulin (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=related_link\">",
"      Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_20_24907="Diet for pediatric hypertriglyceridemia";
var content_f24_20_24907=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diet for pediatric hypertriglyceridemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Refer to a registered dietitian for family medical nutrition therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Dietary components include:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          25 to 30 percent of calories from fat, &le;7 percent from saturated fat, ~10 percent from monounsaturated fat; &lt;200 mg/d of cholesterol; avoid trans fats as much as possible.",
"         </li>",
"         <li>",
"          Decrease sugar intake, replace simple with complex carbohydrates, and no sugar sweetened beverages.",
"         </li>",
"         <li>",
"          Increase dietary fish to increase omega-3 fatty acid.&nbsp;&nbsp;Environmental Protection Agency is advising women of childbearing age who may become pregnant, pregnant women,&nbsp;nursing mothers, and young children to avoid some types of fish and shellfish and eat fish and shellfish that are low in mercury. For more information, call the United States Food and Drug Administration's FDA) food information line toll free at 1-888-SAFEFOOD or visit file://www.cfsan.fda.gov/~dms/admehg3.",
"         </li>",
"         <li>",
"          If child is obese, nutrition therapy should include calorie restriction and increased activity.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Daniels SR, Benuck I, Christakis DA, et al. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Full report, 2011. National Heart Lung and Blood Institute. Available at:",
"     <a href=\"file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf\" target=\"_blank\">",
"      file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_20_24907=[""].join("\n");
var outline_f24_20_24907=null;
var title_f24_20_24908="Resident rating actual patients";
var content_f24_20_24908=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F63274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F63274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ratings of residents' data gathering interviewing skills with actual patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Variable",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Posttest",
"means*",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        P",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Untrained (n = 27)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Trained (n = 28)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encourages responses",
"       </td>",
"       <td>",
"        5.5",
"       </td>",
"       <td>",
"        5.9",
"       </td>",
"       <td>",
"        &gt;0.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allows talking",
"       </td>",
"       <td>",
"        6.5",
"       </td>",
"       <td>",
"        7.2",
"       </td>",
"       <td>",
"        0.078",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Responds to emotions&bull;",
"       </td>",
"       <td>",
"        4.0",
"       </td>",
"       <td>",
"        6.3",
"       </td>",
"       <td>",
"        0.001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pursues biomedical",
"       </td>",
"       <td>",
"        7.8",
"       </td>",
"       <td>",
"        7.1",
"       </td>",
"       <td>",
"        0.086",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pursues psychosocial",
"       </td>",
"       <td>",
"        2.6",
"       </td>",
"       <td>",
"        4.6",
"       </td>",
"       <td>",
"        0.008",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dominates interview",
"       </td>",
"       <td>",
"        5.1",
"       </td>",
"       <td>",
"        4.6",
"       </td>",
"       <td>",
"        0.078",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Builds rapport",
"       </td>",
"       <td>",
"        6.2",
"       </td>",
"       <td>",
"        6.7",
"       </td>",
"       <td>",
"        0.090",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Track patient",
"       </td>",
"       <td>",
"        6.2",
"       </td>",
"       <td>",
"        6.8",
"       </td>",
"       <td>",
"        0.090",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Manages interview",
"       </td>",
"       <td>",
"        5.5",
"       </td>",
"       <td>",
"        6.2",
"       </td>",
"       <td>",
"        0.104",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patient-centered",
"       </td>",
"       <td>",
"        5.0",
"       </td>",
"       <td>",
"        6.1",
"       </td>",
"       <td>",
"        0.009",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overall rating",
"       </td>",
"       <td>",
"        4.2",
"       </td>",
"       <td>",
"        5.6",
"       </td>",
"       <td>",
"        0.011",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Post-test means on an 11-point scale adjusted for pretest scores.",
"     <br>",
"      &bull; Rated only when patients mention an emotion that should elicit a response; 40 subjects were rated on this item.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Smith, RC, Lyles, JS, Mettler, J, et al, Ann Intern Med 1998; 128:139.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_20_24908=[""].join("\n");
var outline_f24_20_24908=null;
var title_f24_20_24909="Evaluation of asthma mimics";
var content_f24_20_24909=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation of conditions that mimic asthma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Diagnosis",
"      </td>",
"      <td class=\"subtitle1\">",
"       Clinical features",
"      </td>",
"      <td class=\"subtitle1\">",
"       Testing",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Alpha-1 antitrypsin deficiency",
"      </td>",
"      <td>",
"       <p>",
"        Dyspnea",
"       </p>",
"       <p>",
"        Family history emphysema",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Alpha-1 antitrypsin: below 50 to 80 mg/dL (11 micromol/L)",
"       </p>",
"       <p>",
"        Genetic confirmation by isoelectric focusing or DNA PCR",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bronchiectasis",
"      </td>",
"      <td>",
"       <p>",
"        Daily sputum production",
"       </p>",
"       <p>",
"        Cough refractory to bronchodilators",
"       </p>",
"       <p>",
"        Sometimes end-inspiratory squeak",
"       </p>",
"       <p>",
"        May have rhinosinusitis",
"       </p>",
"      </td>",
"      <td>",
"       HRCT thorax: bronchiectasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bronchiolitis",
"      </td>",
"      <td>",
"       <p>",
"        History of respiratory infection, inhalational injury, CTD, or lung transplant",
"       </p>",
"       <p>",
"        Crackles and inspiratory squeaks on exam",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        PFTs: DLCO and oxygen saturation are reduced",
"       </p>",
"       <p>",
"        HRCT thorax: interstitial opacities in a mosaic pattern, inspiratory and expiratory views may show focal air trapping",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cardiac disease*",
"      </td>",
"      <td>",
"       Crackles or wheezes",
"      </td>",
"      <td>",
"       <p>",
"        B type natriuretic peptide: elevated",
"       </p>",
"       <p>",
"        Chest xray: increased interstitial opacities, &plusmn;cardiomegaly",
"       </p>",
"       <p>",
"        Echocardiogram: reduced ejection fraction",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Central airway obstruction",
"      </td>",
"      <td>",
"       <p>",
"        Dyspnea on exertion",
"       </p>",
"       <p>",
"        Sometimes monophonic wheeze or stridor",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        PFTs: flattening of flow volume loop",
"       </p>",
"       <p>",
"        HRCT with 3-D reconstruction: narrowed airway",
"       </p>",
"       <p>",
"        Direct visualization: airway obstruction",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chronic eosinophilic pneumonitis",
"      </td>",
"      <td>",
"       <p>",
"        Asthma predates or develops in over 50 percent of patients",
"       </p>",
"       <p>",
"        Fever, weight loss and night sweats are common",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Peripheral blood: &plusmn;eosinophilia",
"       </p>",
"       <p>",
"        Chest xray: bilateral peripheral opacities",
"       </p>",
"       <p>",
"        BAL: eosinophilia &gt;40 percent",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       COPD*",
"      </td>",
"      <td>",
"       Smoking history",
"      </td>",
"      <td>",
"       PFTs: irreversible airflow obstruction and sometimes low DLCO",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hypersensitivity pneumonitis",
"      </td>",
"      <td>",
"       <p>",
"        Exposure to an inciting agent",
"       </p>",
"       <p>",
"        Abrupt onset fever, chills",
"       </p>",
"       <p>",
"        Dyspnea without wheezing",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        PFTs: restrictive or mixed obstructive/restrictive pattern",
"       </p>",
"       <p>",
"        Chest xray: fleeting pulmonary infiltrates",
"       </p>",
"       <p>",
"        HRCT thorax: ground glass opacities and parenchymal micronodules",
"       </p>",
"       <p>",
"        BAL: lymphocytosis",
"       </p>",
"       <p>",
"        Lung biopsy: poorly formed granulomata",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Obstructive sleep apnea*",
"      </td>",
"      <td>",
"       <p>",
"        Daytime hypersomnolence",
"       </p>",
"       <p>",
"        Nocturnal choking",
"       </p>",
"       <p>",
"        Snoring",
"       </p>",
"      </td>",
"      <td>",
"       Polysomnogram: elevated respiratory disturbance index",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sarcoidosis* (endobronchial)",
"      </td>",
"      <td>",
"       <p>",
"        Nonproductive cough",
"       </p>",
"       <p>",
"        Dyspnea",
"       </p>",
"       <p>",
"        Cutaneous stigmata of sarcoidosis",
"       </p>",
"       <p>",
"        May have nasal or sinus sarcoid",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Chest xray: Hilar adenopathy with or without interstitial opacities",
"       </p>",
"       <p>",
"        PFTs: restriction and reduced DLCO",
"       </p>",
"       <p>",
"        Endobronchial biopsy: noncaseating granulomata",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Strongyloidiasis, filariasis",
"      </td>",
"      <td>",
"       Travel to endemic country",
"      </td>",
"      <td>",
"       <p>",
"        Peripheral blood: eosinophilia",
"       </p>",
"       <p>",
"        IgG antibodies to strongyloides or filaria: positive",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vocal cord dysfunction*",
"      </td>",
"      <td>",
"       <p>",
"        Hoarseness/stridor (can be inspiratory and/or expiratory)",
"       </p>",
"       <p>",
"        Symptoms provoked by exercise",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Flow volume loop: slowing on inspiration",
"       </p>",
"       <p>",
"        Direct laryngoscopy (possibly during exercise or methacholine challenge): abnormal cord motion",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ANCA: antineutrophil cytoplasmic antibodies; BAL: bronchoalveolar lavage; CTD: connective tissue disease; DLCO: diffusing capacity; GERD: gastroesophageal reflux disease; HRCT: high resolution computed tomography; PFTs: pulmonary function testing; PPI: proton pump inhibitor.",
"     <br>",
"      * These conditions can also co-occur with asthma",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_20_24909=[""].join("\n");
var outline_f24_20_24909=null;
var title_f24_20_24910="Crash airway algorithm";
var content_f24_20_24910=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The crash airway algorithm&copy;",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 463px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Difficult Airway Course&reg;: Emergency and Walls RM, Murphy MF. Manual of Emergency Airway Management,&nbsp;4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_20_24910=[""].join("\n");
var outline_f24_20_24910=null;
var title_f24_20_24911="Evaluation algorithm for morphea";
var content_f24_20_24911=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Algorithm for the evaluation of patients with morphea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 524px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_20_24911=[""].join("\n");
var outline_f24_20_24911=null;
